Analyte monitoring system and method

Abstract
Devices and methods for monitoring an analyte are provided. Embodiments include continuous analyte sensors having a high degree of accuracy.
Description
BACKGROUND OF THE INVENTION

The association of chronic hyperglycemia and the devastating long-term complications of diabetes was clearly established by the Diabetes Control and Complication Trial (DCCT) (The Diabetes Control and Complications Trial Research Group. “The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus” N Engl J Med 329: 978-986, 1993; Santiago J V “Lessons from the Diabetes Control and Complications Trial” Diabetes 1993, 42: 1549-1554).


The DCCT found that in patients receiving intensive insulin therapy, there was a reduced risk of 76% for diabetic retinopathy, 50% for diabetic nephropathy and 60% for diabetic neuropathy. The long-term benefits of tight glycemic control have been further substantiated by the Epidemiology of Diabetes Interventions and Complications study which found over a 50% reduced risk of macrovascular disease as a result of intensive insulin therapy (The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complication (DCCT/EDIC) Study Group, “Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes”, 353, 2643-2653, 2005).


However, the DCCT found that patients receiving intensive insulin therapy were at a threefold increased risk of severe hypoglycemia. Patients adhering to intensive insulin therapy regimens were found to have lowered thresholds for activation of neurogenic warning systems and consequently were at increased risk for more severe hypoglycemic events. (Amiel S A, Tamborlane W V, Simonson D C, Sherwin R S., “Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus.” N Engl J. Med. 1987 28; 316(22):1376-83).


The increased risk of hypoglycemia and the fear associated with patients' perception of that risk has been cited as the leading obstacle for patients to achieve the targeted glycemic levels (Cryer P E. “Hypoglycaemia: The limiting factor in the glycemic management of type I and type II diabetes” Diabetologia, 2002, 45: 937-948). In addition to the problem of chronic hyperglycemia contributing to long-term complications and the problem of acute iatrogenic hypoglycemia contributing to short-term complications, recent research suggests that transient episodes of hyperglycemia can lead to a wide range of serious medical problems besides previously identified microvascular complications as well as macrovascular complications such as increased risk for heart disease. (Haffner S “The importance of postprandial hyperglycemia in development of cardiovascular disease in people with diabetes” International Journal of Clinical Practice, 2001, Supplement 123: 24-26; Hanefeld M: “Postprandial hyperglycemia: noxious effects on the vessel wall” International Journal of Clinical Practice, 2002, Supplement 129: 45-50).


Additional research has found that glycemic variation and the associated oxidative stress may be implicated in the pathogenesis of diabetic complications (Hirsh I B, Brownlee M “Should minimal blood glucose variability become the gold standard of glycemic control?” J of Diabetes and Its Complications, 2005, 19: 178-181; Monnier, L., Mas, E., Ginet, C., Michel, F., Villon L, Cristol J-P, and Collette C, “Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes”. JAMA 2006, 295, 1681-1687). Glycemic variation has also been identified as a possible explanation for the increased prevalence of depression in both type 1 and type 2 diabetes (Van der Does F E. De Neeling J N, Snoek F J, Kostense P J, Grootenhuis P A, Bouter L M, and R J Heine: Symptoms and well-being in relation to glycemic control in type II diabetes Diabetes Care, 1996, 19: 204-210; De Sonnaville J J. Snoek F J. Colly L P. Deville W. Wijkel D. Heine R J: “Well-being and symptoms in relation to insulin therapy in type 2 diabetes” Diabetes Care, 1998, 21:919-24; Cox D J, Gonder-Frederick L A, McCall A, et al. “The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes” International Journal of Clinical Practice, 2002, Supplement 129: 20-26).


The potential benefits of continuous glucose monitoring have been recognized by numerous researchers in the field (Skyler J S “The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system” Diabetes Technol Ther 2 (Suppl 1): S7-S12, 2000; Tansey M J, Beck R W, Buckingham B A, Mauras N, Fiallo-Scharer R, Xing D, Kollman C, Tamborlane W V, Ruedy K J, “Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study.” Diab. Tech. Ther. 7(1):109-14, 2005; Klonoff, D C: “Continuous glucose monitoring: Roadmap for 21st century diabetes therapy” Diabetes Care, 2005, 28: 1231:1239). Accurate and reliable real-time continuous glucose monitoring devices have the ability to alert patients of high or low blood sugars that might otherwise be undetected by episodic capillary blood glucose measurements.


Continuous glucose monitors have the potential to permit more successful adherence to intensive insulin therapy regimens and also to enable patients to reduce the frequency and extent of glycemic fluctuations. However, the development of this technology has proceeded more slowly than anticipated. For example, two recent comprehensive reviews of decades of research in the field cited the lack of accuracy and reliability as the major factor limiting the acceptance of this new technology as well as the development of an artificial pancreas (Chia, C. W. and Saudek, C. D., “Glucose sensors: toward closed loop insulin delivery” Endocrinol. Metab. Clin. N. Am., 33, 174-195, 2004; Hovorka, R. “Continuous glucose monitoring and closed-loop systems” Diabet. Med. 23, 1-12, 2006).


As continuous analyte monitoring becomes more prevalent, of use are continuous analyte sensors and systems that are accurate to such a high degree that confirmatory analyte measurement are not needed to verify the continuous sensing measurements, e.g., prior to a user relying on the continuous measurements. Also of interest are such sensors that work in concert with a drug delivery device.


SUMMARY OF THE INVENTION

Generally, the present disclosure relates to methods and devices for monitoring of the level of an analyte using a continuous and/or automatic in vivo monitoring analyte sensor. Embodiments include sensors in which at least a portion of the sensor is adapted to be positioned beneath the skin of a user and which are adapted for providing clinically accurate analyte data, i.e., data with accuracy sufficient so that a user may confidently rely on the sensor results, e.g., to manage a disease condition and/or make a healthcare decision based thereon. Accordingly, sensors capable of providing clinically accurate (i.e., clinically relevant) analyte information to a user are provided.


Embodiments include continuous analyte monitoring systems that do not require additional analyte information obtained by a second system and/or sensor to confirm the results reported by the continuous sensing system.


Embodiments also include high accuracy continuous analyte sensors and systems with drug delivery systems e.g., insulin pumps, or the like. A communication link (e.g., by cable or wirelessly such as by infrared (IR) or RF link or the like) may be provided for transfer of data from the sensor to the drug delivery device. The drug delivery device may include a processor to determine the amount of drug to be delivered using sensor data, and may deliver such drug automatically or after user direction to do so.


Also provided are methods of analyte monitoring using highly accurate continuous analyte sensors.


These and other objects, features and advantages of the present disclosure will become more fully apparent from the following detailed description of the embodiments, the appended claims and the accompanying drawings.





BRIEF DESCRIPTIONS OF THE DRAWINGS

The figures shown herein are not necessarily drawn to scale, with some components and features being exaggerated for clarity. Each of the figures diagrammatically illustrates aspects of the present disclosure. Of these:



FIG. 1 is a block diagram of one embodiment of a highly accurate continuous glucose monitoring system such as Freestyle Navigator® system using a subcutaneously implantable analyte sensor, according to one embodiment of the present disclosure;



FIG. 2 shows five day accuracy data for the monitoring system of FIG. 1 (arm and abdomen) and 50 hours of YSI venous sampling in one embodiment;



FIG. 3 shows a Clarke error grid for the continuous monitoring system of FIG. 1 in one embodiment;



FIG. 4A shows a view (four hour duration) of profile plot centered glucose challenge, and FIG. 4B shows a view (four hour duration) of profile plot centered insulin challenge;



FIG. 5 shows rate of change histogram showing underlying rate of change at high resolution (in units of 0.25 mg/dL/min) and in units of the continuous monitoring system of FIG. 1 receiver trend arrows (1.0 mg/dL/min);



FIG. 6 shows a Clarke error grid for YSI rates of change between −1 to 1 mg/dL/min;



FIG. 7 shows the Clarke error grid from a high accurate continuous glucose monitoring system user study; and



FIG. 8 illustrates the time spent in hypoglycemic, euglycemic, and hyperglycemic ranges for type 1 and 2 subjects in the blinded and unblinded phases of the study described in conjunction with FIG. 7.





DETAILED DESCRIPTION

Before the various embodiments of the present disclosure is described, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.


Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the present disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the present disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the present disclosure.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of various embodiments of the present disclosure, exemplary methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.


It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.


The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.


As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.


The present disclosure is applicable to analyte monitoring systems using a sensor—at least a portion of which is positioned beneath the skin of the user, for the in vivo determination of a concentration of an analyte, such as glucose, lactate, and the like, in a body fluid. The sensor may be, for example, subcutaneously positioned in a patient for the continuous or periodic monitoring an analyte in a patient's interstitial fluid. This may be used to infer the glucose level in the patient's bloodstream. The sensors of the subject disclosure also include in vivo analyte sensors for insertion into a vein, artery, or other portion of the body containing fluid. A sensor of the subject disclosure may be configured for monitoring the level of the analyte over a time period which may range from hours, days, weeks, or longer, as described in greater detail below.


More specifically, FIG. 1 illustrates a data monitoring and management system such as, for example, analyte (e.g., glucose) monitoring system 100, in accordance with one embodiment of the present disclosure. The subject disclosure is further described primarily with respect to a glucose monitoring system for convenience and such description is in no way intended to limit the scope of the present disclosure. It is to be understood that the analyte monitoring system may be configured to monitor a variety of analytes. Analytes that may be monitored include, for example, acetyl choline, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase (e.g., CK-MB), creatine, DNA, fructosamine, glucose, glutamine, growth hormones, hormones, ketones, lactate, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, and troponin, and the like. The concentration of drugs, such as, for example, antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, drugs of abuse, theophylline, and warfarin, and the like, may also be monitored.


The analyte monitoring system 100 includes a highly accurate sensor 101, a transmitter unit 102 coupled to the sensor 101, and a receiver unit 104 which is configured to communicate with the transmitter unit 102 via a communication link 103. The receiver unit 104 may be further configured to transmit data to a data processing terminal 105 for evaluating the data received by the receiver unit 104. Moreover, the data processing terminal in one embodiment may be configured to receive data directly from the transmitter unit 102 via a communication link 106 which may optionally be configured for bi-directional communication. Some or all of the various components may be separate components, or some or all may be integrated into a single unit.


Only one sensor 101, transmitter unit 102, receiver unit 104, communication link 103, and data processing terminal 105 are shown in the embodiment of the analyte monitoring system 100 illustrated in FIG. 1. However, it will be appreciated by one of ordinary skill in the art that the analyte monitoring system 100 may include one or more sensor 101, transmitter unit 102, receiver unit 104, communication link 103, and data processing terminal 105. Moreover, within the scope of the present disclosure, the analyte monitoring system 100 may be a continuous monitoring system, or semi-continuous, or a discrete monitoring system. In a multi-component environment, each device is configured to be uniquely identified by each of the other devices in the system so that communication conflict is readily resolved between the various components within the analyte monitoring system 100.


In one embodiment of the present disclosure, the sensor 101 is physically positioned in or on the body of a user whose analyte level is being monitored. The sensor 101 may be configured to continuously sample the analyte level of the user and convert the sampled analyte level into a corresponding data signal for transmission by the transmitter unit 102. In one embodiment, the transmitter unit 102 is coupled to, e.g., mounted on, the sensor 101 so that both devices are positioned on the user's body. The transmitter unit 102 performs data processing such as filtering and encoding on data signals, each of which corresponds to a sampled analyte level of the user, for transmission to the receiver unit 104 via the communication link 103.


In one embodiment, the analyte monitoring system 100 is configured as a one-way RF communication path from the transmitter unit 102 to the receiver unit 104. In such embodiment, the transmitter unit 102 transmits the sampled data signals received from the sensor 101 without acknowledgement from the receiver unit 104 that the transmitted sampled data signals have been received. For example, the transmitter unit 102 may be configured to transmit the encoded sampled data signals at a fixed rate (e.g., at one minute intervals) after the completion of the initial power on procedure. Likewise, the receiver unit 104 may be configured to detect such transmitted encoded sampled data signals at predetermined time intervals. Alternatively, the analyte monitoring system 100 may be configured with a bi-directional RF (or otherwise) communication between the transmitter unit 102 and the receiver unit 104.


Additionally, in one aspect, the receiver unit 104 may include two sections. The first section is an analog interface section that is configured to communicate with the transmitter unit 102 via the communication link 103. In one embodiment, the analog interface section may include an RF receiver and an antenna for receiving and amplifying the data signals from the transmitter unit 102, which are thereafter, demodulated with a local oscillator and filtered through a band-pass filter. The second section of the receiver unit 104 is a data processing section which is configured to process the data signals received from the transmitter unit 102 such as by performing data decoding, error detection and correction, data clock generation, and data bit recovery.


In certain embodiments, in operation, the receiver unit 104 is configured to detect the presence of the transmitter unit 102 within its range based on, for example, the strength of the detected data signals received from the transmitter unit 102 or a predetermined transmitter identification information. Upon successful synchronization with the corresponding transmitter unit 102, the receiver unit 104 is configured to begin receiving from the transmitter unit 102 data signals corresponding to the user's detected analyte level. More specifically, the receiver unit 104 in one embodiment is configured to perform synchronized time hopping with the corresponding synchronized transmitter unit 102 via the communication link 103 to obtain the user's detected analyte level.


Referring again to FIG. 1, the data processing terminal 105 may include a personal computer, a portable computer such as a laptop or a handheld device (e.g., personal digital assistants (PDAs)), and the like, each of which may be configured for data communication with the receiver via a wired or a wireless connection. Additionally, the data processing terminal 105 may further be connected to a data network (not shown) for storing, retrieving and updating data corresponding to the detected analyte level of the user.


Within the scope of the present disclosure, the data processing terminal 105 may include an infusion device such as an insulin infusion pump or the like, which may be configured to administer insulin to patients, and which may be configured to communicate with the receiver unit 104 for receiving, among others, the measured analyte level. Alternatively, the receiver unit 104 may be configured to integrate an infusion device therein so that the receiver unit 104 is configured to administer insulin therapy to patients, for example, for administering and modifying basal profiles, as well as for determining appropriate boluses for administration based on, among others, the detected analyte levels received from the transmitter unit 102.


Additionally, the transmitter unit 102, the receiver unit 104 and the data processing terminal 105 may each be configured for bi-directional wireless communication such that each of the transmitter unit 102, the receiver unit 104 and the data processing terminal 105 may be configured to communicate (that is, transmit data to and receive data from) with each other via the wireless communication link 103. More specifically, the data processing terminal 105 may in one embodiment be configured to receive data directly from the transmitter unit 102 via the communication link 106, where the communication link 106, as described above, may be configured for bi-directional communication.


In this embodiment, the data processing terminal 105 which may include an insulin pump, may be configured to receive the analyte signals from the transmitter unit 102, and thus, incorporate the functions of the receiver 103 including data processing for managing the patient's insulin therapy and analyte monitoring. In one embodiment, the communication link 103 may include one or more of an RF communication protocol, an infrared communication protocol, a Bluetooth enabled communication protocol, an 802.11x wireless communication protocol, or an equivalent wireless communication protocol which would allow secure, wireless communication of several units (for example, per HIPPA requirements) while avoiding potential data collision and interference.


Continuous Glucose Monitoring Sensors and Systems


As described above, the various embodiments of the present disclosure relate to continuous analyte sensors and systems having a high degree of accuracy, e.g., as demonstrated by a Clark Error Grid, Parks Error Grid, Continuous Glucose Error Grid, MARD analysis, and the like. The high degree of accuracy permits a user to rely on the results of the sensor without the need to confirm sensor results. In certain embodiments, the sensors have at least about 80% of its paired data points within zone A of one or more of the Clark Error Grid, the Consensus Error Grid, or the Continuous Glucose Error Grid Analysis, e.g., at least about 85% of its paired data points within zone A of one or more of the Clark Error Grid, the Consensus Error Grid, or the Continuous Glucose Error Grid Analysis, e.g., at least about 90% of its paired data points within zone A of one or more of the Clark Error Grid, the Consensus Error Grid, or the Continuous Glucose Error Grid Analysis, e.g., at least about 95% of its paired data points within zone A of one or more of the Clark Error Grid, the Consensus Error Grid, or the Continuous Glucose Error Grid Analysis.


In certain embodiments, a sensor may have about 80% or greater, e.g., 85% or greater, e.g., 90% or greater of its paired data points within zone A of the Clark Error Grid, and 80% or greater, e.g., 85% or greater, e.g., 90% or greater, of its paired data points within zone A of the Consensus Error Grid.


The sensors are continuous analyte monitoring sensors. The sensors are adapted to continuously or periodically monitor analyte levels for a period of time, e.g., usually at least about 24 hours, e.g., about 1 day to about 30 days, e.g., about 3 days to about 7 days, e.g., a 5 day sensor or 7 day sensor.


Embodiments of the clinically accurate continuous glucose monitoring systems of the present disclosure include four components: a small, miniaturized analyte sensor element (which may be an electrochemical or optical sensor) for placement in the subcutaneous adipose tissue in the arm or abdomen (or elsewhere); a disposable sensor delivery unit containing a spring-loaded sharp for mechanical insertion of the sensor into the tissue and a sensor support mount; a transmitter (e.g., wireless transmitter) which connects to the sensor support mount on the skin surface and to the inserted electrochemical sensor; and a hand-held receiver device for communication (e.g., wireless) with the transmitter and for the communication (e.g., audio and/or visual display) of the continuous glucose values to the user. The system may also include a data management system in which information from the receiver (and/or transmitter) is forwarded (e.g., wirelessly or otherwise) to a data management system such as a personal computer (“PC”), personal digital assistant (“PDA”), telephone, facsimile machine, drug delivery device (e.g., internal or external insulin pump) or the like.


Embodiments of the sensors of the present disclosure vary, but in all embodiments have a high degree of accuracy. In other words, the sensors' accuracy enables a user of the system to solely and confidently rely on the sensors' results that are reportable to the user, e.g., to manage a disease state such as diabetes or the like, make healthcare decisions (e.g., insulin delivery, meals, exercise, etc.). In this manner, adjunctive measurements are not required to confirm the readings of the highly accurate sensors of the present disclosure, thereby eliminating burdensome and painful fingersticks required for testing analyte using conventional blood analyte monitoring systems such as blood glucose test strips and the like, used for such confirmations.


In certain embodiments a sensor is adapted to be wholly or partially positioned beneath the skin surface of a user. A sensor may be a transcutaneous sensor in which a portion of the sensor is configured to be positioned beneath a skin surface and portion is configured to be positioned above the skin surface. In many embodiments at least a portion of the sensor is configured to be inserted into the subcutaneous adipose tissue. Sensors may vary in size, where in certain embodiments a sensor may be about 5.5 mm long, about 600 microns wide and about 250 microns thick. Sensors having different lengths and/or widths and/or thicknesses are also encompassed by the present disclosure. The sensors are configured to accurately measure an analyte, e.g., glucose concentration in the interstitial fluid, which has correlates with blood glucose. The sensor is typically provided to a user as a sterile, single-use disposable element.


The sensors may be configured to continuously monitor analyte levels of a user for a period of time. In certain embodiments, the period of time ranges from about 1 day to about 30 days, e.g., from about 3 days to about 7 days, where in certain embodiments a sensor may configured for up to about five days of continuous use. A system may include two or more sensors, which may be temporally overlapped for a certain period of usage time, thereby extending the amount of time of continuous sensing and/or doing away with any time gaps that may result from removing a first sensor and inserting a second. Furthermore, a sensor may be calibrated from a previous sensor in certain embodiments.


The glucose measurement is made using sensing chemistry. Sensing chemistry may include an enzyme and may include a mediator. In certain embodiments, the sensing chemistry is a modified glucose oxidase polymeric matrix with an osmium dopant in the supporting polymer matrix. The sensing chemistry (also referred to as the “transduction chemistry”) used in the sensors of the present disclosure permits detection of signal, e.g., a nanoampere electrical current from the reaction with an applied potential, such as of only about 40 mV.


More specifically, in one embodiment, the sensor includes at least one working electrode formed on a substrate. The sensor may also include at least one counter electrode (or counter/reference electrode) and/or at least one reference electrode. The counter electrode and/or reference electrode may be formed on the substrate or may be separate units. For example, the counter electrode and/or reference electrode may be formed on a second substrate which is also implanted in the patient or, for some embodiments of the implantable sensors, the counter electrode and/or reference electrode may be placed on the skin of the patient with the working electrode or electrodes being implanted into the patient.


The working electrode or electrodes are formed using conductive traces disposed on the substrate. The counter electrode and/or reference electrode, as well as other optional portions of the sensor, such as a temperature probe, may also be formed using conductive traces disposed on the substrate. These conductive traces may be formed over a smooth surface of the substrate or within channels formed by, for example, embossing, indenting or otherwise creating a depression in the substrate.


A sensing layer is often formed proximate to or on at least one of the working electrodes to facilitate the electrochemical detection of the analyte and the determination of its level in the sample fluid, particularly if the analyte can not be electrolyzed at a desired rate and/or with a desired specificity on a bare electrode. The sensing layer may include an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode. The sensing layer may also contain a catalyst to catalyze a reaction of the analyte. The components of the sensing layer may be in a fluid or gel that is proximate to or in contact with the working electrode. Alternatively, the components of the sensing layer may be disposed in a polymeric or sol-gel matrix that is proximate to or on the working electrode. In one aspect, the components of the sensing layer are non-leachably disposed within the sensor. Further, the components of the sensor are immobilized within the sensor.


In addition to the electrodes and the sensing layer, the sensor may also include a temperature probe, a mass transport limiting layer, a biocompatible layer, and/or other optional components, as described below. Each of these items enhances the functioning of and/or results from the sensor, as discussed below.


The Substrate


The substrate may be formed using a variety of non-conducting materials, including, for example, polymeric or plastic materials and ceramic materials. Suitable materials for a particular sensor may be determined, at least in part, based on the desired use of the sensor and properties of the materials.


In some embodiments, the substrate is flexible. In other embodiments, the sensors are made using a relatively rigid substrate to, for example, provide structural support against bending or breaking.


Conductive Traces


At least one conductive trace is formed on the substrate for use in constructing a working electrode. In addition, other conductive traces may be formed on the substrate for use as electrodes (e.g., additional working electrodes, as well as counter, counter/reference, and/or reference electrodes) and other components, such as a temperature probe. The conductive traces may be formed on the substrate by a variety of techniques, including, for example, photolithography, screen printing, or other impact or non-impact printing techniques. The conductive traces may also be formed by carbonizing conductive traces in an organic (e.g., polymeric or plastic) substrate using a laser.


The conductive traces are typically formed using a conductive material 56 such as carbon (e.g., graphite), a conductive polymer, a metal or alloy (e.g., gold or gold alloy), or a metallic compound (e.g., ruthenium dioxide or titanium dioxide). The formation of films of carbon, conductive polymer, metal, alloy, or metallic compound are well-known and include, for example, chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, and painting.


In addition to the particles of carbon, metal, alloy, or metallic compound, the conductive ink may also contain a binder. The binder may optionally be cured to further bind the conductive material within the channel and/or on the substrate.


Suitable redox couples for binding to the conductive material of the reference electrode include, for example, redox polymers (e.g., polymers having multiple redox centers.). In one aspect, the reference electrode surface may be non-corroding so that an erroneous potential is not measured. Examples of conductive materials include less corrosive metals, such as gold and palladium, and may include non-corrosive materials including non-metallic conductors, such as carbon and conducting polymers. A redox polymer can be adsorbed on or covalently bound to the conductive material of the reference electrode, such as a carbon surface of a conductive trace. Non-polymeric redox couples can be similarly bound to carbon or gold surfaces.


A variety of methods may be used to immobilize a redox polymer on an electrode surface. One method is adsorptive immobilization. This method is particularly useful for redox polymers with relatively high molecular weights. The molecular weight of a polymer may be increased, for example, by cross-linking.


Another method for immobilizing the redox polymer includes the functionalization of the electrode surface and then the chemical bonding, often covalently, of the redox polymer to the functional groups on the electrode surface.


Sensing Layer


Some analytes, such as oxygen, can be directly electrooxidized or electroreduced on the working electrode. Other analytes, such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electrooxidation or electroreduction of the analyte. Catalysts may also be used for those analyte, such as oxygen, that can be directly electrooxidized or electroreduced on the working electrode. For these analytes, each working electrode has a sensing layer formed proximate to or on a working surface of the working electrode. Typically, the sensing layer is formed near or on only a small portion of the working electrode, often near a tip of the sensor. This limits the amount of material needed to form the sensor and places the sensing layer 64 in the best position for contact with the analyte-containing fluid (e.g., a body fluid, sample fluid, or carrier fluid).


Electron Transfer Agent


In many embodiments, the sensing layer contains one or more electron transfer agents in contact with the conductive material of the working electrode. In some embodiments of the present disclosure, there is little or no leaching of the electron transfer agent away from the working electrode during the period in which the sensor is implanted in the patient. A diffusing or leachable (i.e., releasable) electron transfer agent often diffuses into the analyte-containing fluid, thereby reducing the effectiveness of the electrode by reducing the sensitivity of the sensor over time.


In some embodiments of the present disclosure, to prevent leaching, the electron transfer agents are bound or otherwise immobilized on the working electrode or between or within one or more membranes or films disposed over the working electrode. The electron transfer agent may be immobilized on the working electrode using, for example, a polymeric or sol-gel immobilization technique. Alternatively, the electron transfer agent may be chemically (e.g., ionically, covalently, or coordinatively) bound to the working electrode, either directly or indirectly through another molecule, such as a polymer, that is in turn bound to the working electrode.


In general, electron transfer agents may be electroreducible and electrooxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE). Further, the electron transfer agents are not more reducing than about −150 mV and not more oxidizing than about +400 mV versus SCE.


Catalyst


The sensing layer may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. In one aspect, the catalyst is non-leachably disposed on the sensor, whether the catalyst is part of a solid sensing layer in the sensor or solvated in a fluid within the sensing layer. In a further aspect, the catalyst is immobilized within the sensor (e.g., on the electrode and/or within or between a membrane or film) to prevent unwanted leaching of the catalyst away from the working electrode and into the patient. This may be accomplished, for example, by attaching the catalyst to a polymer, cross linking the catalyst with another electron transfer agent (which can be polymeric), and/or providing one or more barrier membranes or films with pore sizes smaller than the catalyst.


Biocompatible Layer


An optional film layer is formed over at least that portion of the sensor which is subcutaneously inserted into the patient. This optional film layer may serve one or more functions. The film layer prevents the penetration of large biomolecules into the electrodes. This is accomplished by using a film layer having a pore size that is smaller than the biomolecules that are to be excluded. Such biomolecules may foul the electrodes and/or the sensing layer thereby reducing the effectiveness of the sensor and altering the expected signal amplitude for a given analyte concentration. The fouling of the working electrodes may also decrease the effective life of the sensor. The biocompatible layer may also prevent protein adhesion to the sensor, formation of blood clots, and other undesirable interactions between the sensor and body.


Interferent-Eliminating Layer


An interferent-eliminating layer may be included in the sensor. The interferent-eliminating layer may be incorporated in the biocompatible layer or in the mass transport limiting layer (described below) or may be a separate layer. Interferents are molecules or other species that are electroreduced or electrooxidized at the electrode, either directly or via an electron transfer agent, to produce a false signal. In one embodiment, a film or membrane prevents the penetration of one or more interferents into the region around the working electrodes. In one aspect, this type of interferent-eliminating layer is much less permeable to one or more of the interferents than to the analyte.


Mass Transport Limiting Layer


A mass transport limiting layer may be included with the sensor to act as a diffusion-limiting barrier to reduce the rate of mass transport of the analyte, for example, glucose or lactate, into the region around the working electrodes. By limiting the diffusion of the analyte, the steady state concentration of the analyte in the proximity of the working electrode (which is proportional to the concentration of the analyte in the body or sample fluid) can be reduced. This extends the upper range of analyte concentrations that can still be accurately measured and may also expand the range in which the current increases approximately linearly with the level of the analyte. Particularly useful materials for the film layer are membranes that do not swell in the analyte-containing fluid that the sensor tests.


Suitable membranes include 3 to 20,000 nm diameter pores. Membranes having 5 to 500 nm diameter pores with well-defined, uniform pore sizes and high aspect ratios may be used. In one embodiment, the aspect ratio of the pores may be two or greater, or in one aspect five or greater.


Embodiments of the system include a receiver that includes both the signal processing algorithms and the user interface system for operation of the system and display of the results—although one or both may be incorporated wholly or partially into the transmitter of the system. In operation, the glucose display on the main screen of the receiver is updated during a predetermined time period, e.g., about once a minute or the like, and gives the instantaneous continuous glucose value. Also provided may be the direction and/or rate of change averaged over a predetermined period of time, e.g., the preceding fifteen minutes, or the like. The direction may be communicated using any suitable audio and/or visual indicator(s). For example, direction may be displayed with trend arrows that give quantitative ranges of the rate of change in units of about 1 mg/dL/min from about −2 mg/dL/min to about +2 mg/dL/min. The receiver may also include threshold and/or projected warnings—audible and/or visual warnings. These may be settable at the factory and/or by the user to different glucose levels to provide warnings of actual and impending hypo- or hyperglycemia. Other warnings may also be included, e.g., battery level, and the like. Time-to-calibrate indicators may also be included.


The system may also include a blood glucose (“BG”) meter for use with glucose test strips which may be used for calibration of the continuous glucose sensor, but as noted above, is not needed to confirm the continuous sensor results. The BG meter may be a separate, though connectable component, or may be integrated into the receiver as a single unitary device. For example, the receiver may include a test strip port and a processor to process a reading from the test strip. The built-in blood glucose meter eliminates the possibility of transcription errors during sensor calibration and also provides the user with a backup glucose meter system.


The continuous glucose systems of the present disclosure may be calibrated according to a predetermined calibration schedule. In certain embodiments, this schedule may be limited to factory-only calibration. However in certain embodiments, the calibration schedule may include calibrations by the user. For example, over the period of use of the system, it may be calibrated from about 0 to about 10 times, e.g., from about 1 to about 5 times, e.g., about 4 times. An exemplary calibration schedule may include calibration 4 times over a 5 day period, e.g., at 10, 12, 24 and 72 hours after sensor insertion. In certain embodiments, the system may be configured for single point calibration, e.g., as described in U.S. Pat. No. 6,121,009 and elsewhere. In other embodiments, exemplary calibration schedule may include calibration 1-2 times over a 5-7 day period. The system may be configured to accept calibration values that fall within a certain range or are at least meet a threshold value. For example, calibration values may be accepted for blood glucose input between about 60 and about 300 mg/dL and when the absolute rate of change of glucose is estimated to be less than about 2 mg/dL/min. These constraints on the acceptance of calibration input values are designed to limit the potential adverse effects of the intrinsic physiological lag between interstitial fluid glucose and blood glucose.


In the embodiments in which at least one calibration by the user is required, the system may be configured so that it does not display (i.e., does not report to the user) real-time glucose values from the continuous monitor until the first calibration, e.g., at about ten hours after sensor insertion in certain instances. This delay after insertion is designed so that the initial system calibration is performed after the sensor has reached a stable equilibrium with the surrounding tissue.


Moreover, in one embodiment, the use of fingerstick calibration in response to the Freestyle Navigator® system hypoglycemic alarm may increase the overall system accuracy.


An exemplary, analyte sensor and sensing system having the high accuracy described herein is the Freestyle Navigator® continuous glucose monitoring system from Abbott Diabetes Care, Inc., of Alameda, Calif.


Kits


Finally, kits are also provided. Embodiments of the subject kits may include one or more highly accurate sensors as described herein. Embodiments may also include a sensor insertion device and/or transmitter and/or receiver. Embodiments may also include a drug delivery device such as an insulin pump.


In certain embodiments, a kit may include a blood glucose meter to be used with the continuous sensing system, e.g., for calibration. The meter may be a separate component from continuous sensing components (in which case a communication link for transferring data from the meter to the sensing system (such as to the receiver) may be included) or may be integrated therein, e.g., the receiver may include a blood glucose meter.


The subject kits may also include written instructions for using a sensor. The instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g., CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the Internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.


In many embodiments of the subject kits, the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the one or more sensors and additional reagents (e.g., control solutions), if present, until use.


EXPERIMENTAL

The accuracy of a highly accurate continuous monitoring system such as the Freestyle Navigator® continuous glucose monitoring system measuring glucose in the interstitial fluid is studied, in comparison with a laboratory reference method over five days of sensor wear.


Study Design and Methods


Fifty-eight subjects with Type 1 diabetes ranging in age from 18-64 were enrolled in a multi-center, prospective, single-arm study. Each subject wore two sensors simultaneously—one on the arm and the other on the abdomen. All the FreeStyle Navigator® devices were calibrated with separate capillary fingerstick measurements at 10, 12, 24 and 72 hours after sensor insertion. Data from the continuous glucose monitor was collected at one-minute intervals for the entire study. Measurements from the FreeStyle Navigator® system were compared with reference venous sample measurements taken in an in-patient clinical research center once every fifteen minutes over a fifty hour time period covering a distribution over the entire 120 hour wear period for the Freestyle Navigator® sensor.


The subjects were admitted to a healthcare facility either in the evening or in the morning for sensor insertion. The sensors were inserted by a health care professional on both the lateral or posterior upper arm and the right or left lower abdominal quadrant using the disposable sensor delivery unit. The subjects returned to the clinic approximately nine hours later for the placement of the venous access line and for the calibration of the sensor using the built-in FreeStyle® blood glucose meter. Calibration of the FreeStyle Navigator® device in this study was deliberately scheduled to occur at different times of day as well as both pre- and post-prandially. During two separate periods in which the subjects were in the clinic and venous samples were being taken, each subject was administered intravenous insulin or a 75 gram fast-acting glucose drink, such as Glucola, in order to obtain data for evaluation of the sensor performance during deliberately-induced periods of rapidly-falling and rapidly-rising glucose. Data from the sensor and transmitter were stored in the receiver with a one minute frequency, but were not displayed to the subjects or the clinic staff. Throughout the study, all the subjects continued with their previously established diabetes management regimen. The high frequency and volume of the venous blood samples, 2.5 mL once every fifteen minutes, required a limitation of 50 hours of intensive testing in order to maintain the total volume of blood drawn from each subject within accepted safety limits. Subjects were assigned to different study schedules so as to provide an optimal distribution of the fifty hours of laboratory reference data over the total five day duration of the sensor life.



FIG. 2 illustrates five-day data from the Freestyle Navigator® continuous glucose monitor (arm and abdomen) and 50 hours of YSI venous sampling taken two separate in-patient admissions from one subject. The timing of the glucose and insulin challenges is also shown. The shaded blocks are night time. The black solid line is the Freestyle Navigator® sensor in the arm, the dashed line is the sensor in the abdomen. YSI measurements are shown in white triangles. The plus and cross symbols are the Freestyle Navigator® system blood glucose calibrations for the arm and abdominal sensors, respectively.


Referring to FIG. 2, a typical profile plot for the five-days of the study with one-minute data from the arm and abdominal sensors as well as the fifteen minute venous samples taken over three separate periods during the five days. The glucose concentration from the venous sample was measured using a YSI 2300 STAT Plus™ Glucose & Lactate Analyzer YSI analyzer (YSI Life Sciences, Yellow Springs, Ohio). All YSI measurements were made in duplicate from a single blood sample. YSI measurements were multiplied by 1.12 to obtain plasma equivalent value.


Results


A number of separate metrics were used to evaluate the accuracy and performance of the FreeStyle Navigator® system compared with the venous blood samples measured with the laboratory reference method. These metrics included the Clarke error grid, the Consensus error grid, the mean and median absolute relative difference as well as cross-correlation statistics for comparison of abdominal and upper arm sensors. The sensor performance was evaluated for the entire five days, for each day individually as well as diurnally and nocturnally. Characteristic physiological lag times were derived from analysis of the data. The data was also analyzed using the Continuous Glucose Error Grid Analysis (CG-EGA) (Kovatchev, 2004). Finally, the accuracy of the FreeStyle Navigator® system compared to the venous reference samples was analyzed as a function of the measured rates of change in the underlying blood glucose.


Comparison of the FreeStyle Navigator® continuous glucose measurements with the laboratory reference method (n=20,362) gave a mean absolute relative difference of 12.8% and a median absolute relative difference of 9.3%. The percentage in the clinically-accurate Clarke Error Grid zone A was 81.7% and 16.7% in the clinically-acceptable B zone. This included periods of high rates of change of blood glucose during intravenous glucose and insulin challenges. The precision of the matched Freestyle Navigator® sensors worn on the arm and abdomen had a coefficient of variation of 10% (n=312,953). The accuracy remained unchanged over the five days with the percent of data in the Clarke Error Grid Zone A equal to 82.5% on the first day and 80.9% on the fifth day.


Clinical Accuracy Overall



FIG. 3 shows the Clarke error grid for the study reported herein. More specifically, FIG. 3 illustrates an overall Clarke error grid showing 81.7% in the clinically-accurate A zone, 16.7% of the paired points in the clinically-acceptable or benign error zone B and only 1.7% outside of the A and B zones


The Clarke error grid was developed to assess the clinical implications of new glucose monitoring technology relative to accepted reference methods (Cox D J, Clarke W L, Gonder-Frederick L A, Pohl S, Hoover C, Snyder A, “Accuracy of perceiving blood glucose in IDDM”, Diabetes Care, 8(6):529-36, 1985; Clarke W L, Cox D, Gonder-Frederick L A, Carter W and Pohl S L. “Evaluating clinical accuracy of systems for self-monitoring of blood glucose” Diabetes Care, 10, 622-628, 1987). There were a total of 20,362 paired points for all 58 subjects with YSI venous measurements and Freestyle Navigator® system interstitial fluid glucose measurements. 81.7% of the paired points fell in the Clarke error grid zone A indicating a high level of clinical accuracy. There were 16.7% of the paired points in the clinically-acceptable (benign error) zone “B”, 0.1% in the overtreatment error zone “C”, 1.9% in the failure to detect error zone “D” and 0.01% in the clinically inaccurate and dangerous error zone “E”.


The Consensus error grid has been proposed as an alternative to the original error grid zone demarcations, specifically to eliminate the physical proximity of the clinically-unacceptable D zone with the clinically-accurate A zone in the lower left portion of the grid. The results of the Clarke error grid and the Consensus error grid are summarized in the Table (1) below. The Consensus error grid was also defined with five distinct risk levels, but the definitions were specified in terms of effect on clinical action by the patient. Zone A has no effect. Zone B has little or no effect. Zone C has altered clinical action. Zone D has altered clinical action with significant medical risk. Zone E has altered clinical action with potentially dangerous consequences.


On the Clarke error grid, there were 316 individual points in the D zone. Ninety-five percent of these points were in the lower left quadrant of the error grid.









TABLE (1)







Summary statistics of Clarke and Consensus Error Grid












Clarke

Consensus




Error

Error



Grid

Grid


Zone
%
N = 20362
%
N = 20362














A
81.7
16627
85.5
17419


B
16.7
3398
13.6
2776


C
0.1
19
0.8
161


D
1.6
316
0.03
6


E
0.0
2
0.0
0









On the Consensus error grid, by contrast, the number of points in the significant medical risk D zone is reduced to 6. In addition to the reduction in D zone points, the Consensus error grid shows a higher percentage in the clinically-accurate A zone, a slightly lower percentage in the clinically-acceptable B zone, a slightly higher percentage in the altered clinical action C zone and no points in the dangerous consequence E zone.


The performance of the Freestyle Navigator® system was also assessed using the mean and median absolute relative difference between the sensor interstitial glucose measurements and the YSI venous sample measurements. The mean absolute relative difference was 12.8% and the median absolute relative difference was 9.3%. A comparison of accuracy and performance by day shows that the system's performance on the fifth day is equivalent to the performance of the first or second day. Table (2) contains data with the error grid statistics as well as the mean and median absolute relative difference from the study separated by day.









TABLE (2)







Clarke Error Grid, mean and median absolute relative difference by day













Day 1
Day 2
Day 3
Day 4
Day 5

















Zone
N
%
N
%
N
%
N
%
N
%




















A
4354
82.5
3215
82.4
2903
79.4
1688
84.0
4467
80.9


B
865
16.4
646
16.6
668
18.3
285
14.2
934
16.9


C
12
0.2
4
0.1
1
0.0
0
0.0
2
0.0


D
47
0.9
34
0.9
82
2.2
37
1.8
116
2.1


E
0
0.0
2
0.1
0
0.0
0
0.0
0
0.0


Mean ARD

12.6

12.3

14.1

11.9

13.0


Median ARD

9.4

9.3

9.9

7.8

9.5


Total
5278
100.0
3901
100.0
3654
100.0
2010
100.0
5519
100.0









Additional analysis was done comparing the accuracy and performance of the Freestyle Navigator® system nocturnally and diurnally. The percentage of points in the Clarke error grid A zone was 87.1% at night and 80.6% during the day. The difference in accuracy during the day may be associated with the higher rates of change during the daytime, when all of the glucose and insulin challenges were conducted.


The data from the present study has also been analyzed using the Continuous Glucose Error Grid Analysis (CG-EGA), designed to incorporate the extra temporal dimension of data provided by continuous glucose monitoring systems (Kovatchev et al.). The rate analysis using the CG-EGA gave a 81.1% in the rate error grid A zone, 14.4% in the rate error grid B zone, 1.5% in the rate error grid C zone, 2.3% in the rate error grid D zone, and 0.7% in the rate error grid E zone. The point analysis using the CG-EGA gave a 83.6% in point error grid A zone, 15.0% in point error grid B zone, 0.1% in point error grid C zone, 1.3% in point error grid D zone, and 0% in point error grid E zone. The CG-EGA analysis combining rate and point information revealed that accuracy, measured as a percentage of accurate readings plus benign errors, was 97.5% (94.2% accurate, 3.4% benign). The CG-EGA accuracy stratified by glycemic state gave 60.4% in hypoglycemia (53.1% accurate, 7.3% benign), 99.3% in euglycemia (95.7% accurate, 3.6% benign) and 98.2% in hyperglycemia (95.4% accurate, 2.8% benign). The difference in accuracy between the hypoglycemic, euglycemic, and hyperglycemic ranges may be related to the high rate of change often associated with the descent into hypoglycemia. Standard egression analysis and Deming regression analysis both gave small, but significant offsets 24.9 and 14.3 mg/dL) that could contribute to the slight decrease in accuracy in hypoglycemia.



FIGS. 4A and 4B give an expanded view of the data from FIG. 2 on a four-hour time axis and centered about the glucose challenge and the insulin challenge, respectively. More specifically, FIG. 4A illustrates a zoomed in view (four hour duration) of Freestyle Navigator®™ sensor data and YSI measurements during the glucose challenge. Referring to FIG. 4A, the continuous glucose sensor data in one minute intervals are shown in the two solid curves (solid from the arm, dashed from the abdomen). The 15 minute YSI venous sample data are shown in the triangles. The time between the nadir of the YSI data and the Freestyle Navigator® system is approximately 24 minutes. The time between the peak of the YSI data and the Freestyle Navigator® system data is approximately 19 minutes.


Additionally, FIG. 4B shows data from two Freestyle Navigator® sensors, compared with fifteen minutes venous samples measured with the YSI from the insulin challenge in one patient in the study. Referring to FIG. 4B, the Freestyle Navigator® projected alarm, would have alerted the subject to an impending hypoglycemic event 26 minutes before the blood sugar crossed the 70 mg/dL hypoglycemic threshold. At the time of the alarm, the Freestyle Navigator® system glucose was approximately 175 mg/dL and the YSI reading was approximately 90 mg/dL and the rate of change was −3.5 mg/dL/min.


Both FIGS. 4A and 4B show the temporal tracking of the FreeStyle Navigator® system compared against the venous reference samples. The expanded temporal axis used in FIGS. 4A and 4B also permits more direct visualization of the time lag between the Freestyle Navigator® system interstitial fluid glucose measurement and the venous reference sample measurements. The temporal offset between the FreeStyle® Navigator system and the venous reference measurements was also analyzed by applying a time shift in order to minimize the mean absolute relative difference.


After correction for the calibration bias, this resulted in an average 12.8 minute lag between the glucose values measured in the interstitial fluid and in the venous samples. This is consistent with previously published studies on the physiological lag between interstitial fluid glucose and blood glucose (see for example: Rebrin K, Steil G M, van Antwerp W P, Mastrotoraro J J, “Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring”, Am J Physiol., 277(3 Pt 1):E561-71, 1999; Steil G M, Rebrin K, Mastrototaro J, Bernaba B, Saad M F, “Determination of plasma glucose during rapid glucose excursions with a subcutaneous glucose sensor”, Diab. Tech. Ther, 5:27-31, 2003; Thennadil S N, Rennert J L, Wenzel B J, Hazen K H, Ruchti T L, Block M B, “Comparison of glucose concentration in interstitial fluid, and capillary and venous blood during rapid changes in blood glucose levels”, Diab. Tech. Ther., 3(3):357-65, 2001).


The performance of the arm and abdominal sensors was comparable with equivalent Clarke error grid statistics and mean absolute relative difference. The precision of the matched Freestyle Navigator® sensors worn on the arm and abdomen had a coefficient of variation of 10% (n=312, 953). There was no difference in performance of the sensor as a function of age, gender or ethnicity. However, there were small but measurable differences in the accuracy of the sensor depending on the subject's BMI and also on the years since diagnosis. Subjects with BMI less than 25.0 had 78.8% in the Clarke error grid A zone (N=4844), whereas subjects with BMI between 25.0 and 30.0 had 82.2% in the Clarke error grid A zone (N=7855) and subjects with BMI greater than 30.0 had 84.4% in the Clarke error grid A zone (N=3928). Similarly, there were small but measurable differences in accuracy depending on the years since diagnosis of type 1 diabetes. The highest accuracy, 88.5% in the Clarke error grid A zone, was found in subjects who had been diagnosed with diabetes for five years or less (N=2066) and 81.3% for subjects diagnosed between 5 and 25 years (N=9133). Subjects diagnosed with type 1 diabetes for over 25 years had 79.9% in the Clarke error grid A zone (N=5448).


Clinical Accuracy Under Special Circumstances


The evaluation of the overall accuracy and performance of the FreeStyle Navigator® continuous glucose monitor included periods of deliberately-induced rapidly rising and rapidly falling blood glucose, i.e. in response to the glucose and insulin challenges. There were significant differences in the accuracy compared with the laboratory reference measurements depending on the different rates of change of the underlying blood glucose. Table (3) gives the Clarke error grid statistics and the median absolute relative difference percentage as a function of the rate of change of blood glucose as determined by the YSI measurements. The effect of the physiological lag on the accuracy of the sensor values compared to venous reference samples is more pronounced at the high rates of change, particularly during when the absolute rate of change exceeds 2 mg/dL/min.









TABLE (3)







Rate of change and Clarke error grid statistics and median ARD










Rate of





Change

Clarke Error Grid Region
Median














(mg/dL/min)
N
A
B
C
D
E
ARD %

















<−2
601
54.6
42.3
1.3
1.8
0.0
17.4


−2 to −1
1728
71.7
26.2
0.3
1.8
0.0
11.8


−1 to 1  
14653
84.9
13.5
0.0
1.5
0.0
8.5


1 to 2
1954
79.8
18.9
0.0
1.3
0.0
11.0


  >2
691
63.5
34.7
0.0
1.7
0.0
16.9










FIG. 5 illustrates the rate of change histogram showing underlying rate of change at high resolution (in units of 0.25 mg/dL/min) and in units of the Navigator receiver trend arrows (1.0 mg/dL/min). The rate of change of glucose as measured by the sensor was between −1 and +1 mg/dL/min 74.6% of the time. Referring to FIG. 5, there is a slight difference in the measured occurrence of absolute rates of change less than 1 mg/dL/min due to the different sampling frequency and temporal extent of the Freestyle Navigator® system and YSI measurements.


The Freestyle Navigator® trend arrows would have been in the horizontal position indicating an absolute rate of change less than 1 mg/dL/min 74.1% of the time for which the YSI data revealed 71.9% of all readings in this range. Both values are consistent with previously reported results (see for example: Dunn T C, Eastman R C, Tamada J A, “Rates of glucose change measured by blood glucose meter and the GlucoWatch Biographer during day, night, and around mealtimes”, Diabetes Care 27: 2161-2165, 2004; Kovatchev, B. P., Clarke, W. L., Breton, M., Brayman, K. and McCall, A. “Quantifying Temporal Glucose Variability in Diabetes via Continuous Glucose Monitoring: Mathematical Methods and Clinical Application” Diab. Technol. Thera., 7, 849-862, 2005).



FIG. 6 illustrates Clarke error grid for YSI rates of change between −1 to 1 mg/dL/min showing increase in accuracy during modest rates of change. Referring to FIG. 6, whereas the overall percentage of paired points in the Clarke error grid A zone was 81.7%, the percentage in the A zone for rates of change between −1 mg/dL/min and +1 mg/dL/min was significantly higher at 84.9%. Similarly, the mean and median absolute relative differences at these times were 11.4% and 8.5% respectively.


The accuracy of the Freestyle Navigator® continuous glucose monitor was evaluated in comparison to a standard laboratory reference method using venous blood samples. The overall mean and median absolute relative difference of the sensor in the current study of 12.8% and 9.3% represent a significantly higher level of accuracy than previously published results from other continuous glucose monitoring systems (see for example, Diabetes Research in Children Network (DirecNet) Study Group: “The Accuracy of the CGMS in Children with Type 1 Diabetes: Results of the Diabetes Research in Children Network (DirecNet) Accuracy Study”. Diabetes Technol Ther 5(5):781-789, 2003; Diabetes Research in Children Network (DirecNet) Study Group: “The Accuracy of the GlucoWatch G2 Biographer in Children with Type 1 Diabetes: Results of the Diabetes Research in Children Network (DirecNet) Accuracy Study”. Diabetes Technol Ther 5(5):791-800, 2003; Tansey M J, Beck R W, Buckingham B A, Mauras N, Fiallo-Scharer R, Xing D, Kollman C, Tamborlane W V, Ruedy K J, “Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study.” Diab. Tech. Ther. 7(1):109-14, 2005; Garg S., Zisser H., Schwartz S., Bailey T., Kaplan R., Ellis S. and Jovanovic L, “Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor”, Diabetes Care, 29, 44-50, 2006).


The high accuracy of the system as measured by the percentage in the Clarke error grid A zone and the mean and median absolute relative differences remained high over the entire five days. There was a small, but measurable improvement in the Clarke error grid statistics and the absolute relative difference values on the fourth day. This is due principally to the fact that there were no glucose challenges administered on the fourth day of the study resulting in fewer rates of change on that day less than 2 mg/dL/min than on other days. In addition, there may be a small increase in accuracy on the fourth day associated with the final system calibration at 72 hours after sensor insertion. Similarly, the slight decrease in accuracy observed on the third and fifth days of the sensor wear may be associated with the fact that these days had a greater number of glucose and insulin challenges than other days in the study, resulting in more absolute rates of change on those days in excess of 2 mg/dL/min.


A significant portion of the apparent discrepant points between the Freestyle Navigator® and the venous reference samples are likely due to the physiological lag alone. An example of the effect of physiological lag on accuracy is the point at the nadir of the curves in FIG. 4B, which is categorized in the Clarke error grid analysis as a clinically unacceptable D zone point. In this case, although the point-wise comparison of the Freestyle Navigator® sensor value and the venous reference sample value suggests a failure to detect a hypoglycemic event, it is clear from the data that the Freestyle Navigator® system is correctly tracking the fall of the subject's glucose level.


In the case shown in FIG. 4B, with the projected alarm capability enabled and the detection threshold set at 70 mg/dL, the device would have alerted the user to a predicted change in clinical state from euglycemia to hypoglycemia when the Freestyle Navigator® glucose value was approximately 175 mg/dL and the measured rate of glucose decrease was in excess of −3.5 mg/dL/min. At that moment, the trend arrow was in the downward vertical direction, indicating a rate of glucose decrease of greater than 2 mg/dL/min, and the device's alarm would have used predictive algorithm to identify that the subject would be hypoglycemic in thirty minutes.


At the time when the projected alarm would have alerted the subject to an impending hypoglycemic event, the YSI reading was approximately 90 mg/dL. An interpolation of the YSI data indicates that the subject's blood sugar crossed the 70 mg/dL threshold for hypoglycemia approximately twenty-six minutes later. Although the paired YSI and Freestyle Navigator® system points at the nadir of the curve result in a D zone point on the Clarke error grid, it is clear from a detailed analysis that the projected alarm would have alerted the subject to an impending hypoglycemic event in a timely manner.


Another important measure of the clinical accuracy, and ultimately the clinical utility, of the Freestyle Navigator®system is the percentage of points in the clinically-accurate Clarke error grid A zone. A recent numerical simulation study evaluated the effect of sensor inaccuracy on the statistics associated with glucose monitoring error grid analysis using data from a clinical trial of a continuous glucose monitoring system in type 1 children and adolescents (Kollman et al., 2005). In the numerical study, paired points from the actual continuous glucose monitoring system and a laboratory reference method were randomly “shuffled” to simulate a high degree of sensor inaccuracy. The study found that 78% of the randomly shuffled paired points were still in the combined A and B zones of the Clarke error grid. A more useful measure of the clinical accuracy and utility of new glucose monitoring technology may be the percentage of points in the clinically-accurate Clarke error grid A zone alone. (Kollman C, Wilson D M, Wysocki T, Tamborlane W V, Beck R W, “Limitations of the Statistical measures of Error in Assessing the Accuracy of continuous Glucose Sensors”, Diab. Tech. Ther., 7(5):665-672, 2005). An alternative to the more commonly-used metric of combined A and B zone percentage is to rely instead on the total percentage in the A zone alone. The results of the present study showing the Freestyle Navigator® system achieving 81.7% in the A zone alone represent a new level of performance for continuous glucose monitoring systems.


The high accuracy and performance of the Freestyle Navigator® system at night is also in contrast with previous reports of continuous glucose monitoring systems that exhibited sustained periods of anomalous nocturnal hypoglycemia (see for example: McGowan K. Thomas W, Moran A. “Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type I diabetes” Diabetes Care 2002; 25: 1499-1503; Metzger My Leibowitz G, Wainstein J, Glaser B, Raz I. “Reproducibility of glucose measurements using the glucose sensor” Diabetes Care 2002; 25: 1185-1191; Mauras N, Beck R W, Ruedy K J, Koliman C, Tamborlane W V, Chase H P “Lack of accuracy of continuous glucose sensors in hialthy nondiabetic children: results of the Diabetes Research in Children Network (DirecNet) accuracy study” J Pediatr 2004; 144:770-775).


The difference in accuracy as a function of BMI may be related to the length of the Freestyle Navigator® sensor and the thickness of the subcutaneous adipose tissue layer in subjects with BMI less than 25. Anthropometric data strongly suggests that the insertion of the Freestyle Navigator® sensor in the upper arm or abdomen will result in the sensor being placed as intended in the subcutaneous adipose tissue layer in most individuals (Horejsi, R., Moller, R., Pieber, T R, Wallner, S., Sudi, K, Reibnegger, G. and Tafeit “Differences of subcutaneous adipose tissue topography between type 2 diabetic men and healthy controls” Exp. Biol. Med., 227, 794-798, 2002). However, in some individuals with low BMI, the data indicate that the subcutaneous adipose tissue layer thickness on the posterior arm upper arm or even the lower abdominal quadrant may be only slightly greater than the required 6 mm thickness needed to properly accommodate the sensor. Although the overall sensor performance in subjects with BMI less than 25 is still excellent (78.8% in the clinically-accurate Clarke error grid A zone), there is a small but measurable difference when compared with subjects with BMI greater than 30 (84.4% in the clinically-accurate Clarke error grid A zone). In the low BMI subjects with reduced subcutaneous adipose tissue layer thickness, the proximity of skeletal muscle tissue to the sensor in the adipose tissue could increase the effect reported by Moberg et al. in which tissue glucose nadirs were not only delayed relative to plasma, but also reduced especially during insulin-induced hypoglycemia (Moberg E, Hagstrom-Toft E, Amer P. and Bolinder J. “Protracted glucose fall in subcutaneous adipose tissue and skeletal muscle compared with blood during insulin-induced hypoglycaemia” Diabetologia 40, 1320-1326, 1997).


In the present study, the apparent difference in accuracy as a function of years since diagnosis is most likely also a result of the weak dependence of accuracy on BMI. The 6 subjects with a diagnosis of diabetes less than five years, for whom there was the highest percentage in the Clarke error grid A zone and the lowest median absolute relative difference, also by chance had the highest mean BMI (29.8). Similarly, the 18 subjects with lowest BMI (<24.9) in the study happened to also have the highest mean years since diagnosis of diabetes (30.1 years).


Insulin Adjustment Procedure—Clinical Decision Analyses

Insulin Adjustment Analysis


The Insulin Adjustment Analysis evaluates the difference between insulin dosing based on Freestyle Navigator® Continuous Glucose Monitoring System (CM) readings and that based on reference readings. The interpretation of the analysis is best understood considering a hypothetical patient with a glucose target level of 90-120 mg/dL and an insulin sensitivity of 30 mg/dL/unit. The glucose target level represents aggressive therapy where the therapeutic goal is to keep glucose squarely in the normal range. The analysis is targeted to meet the requirements of intensive insulin therapy. The choice of insulin sensitivity was made to simplify interpretation—the treatment differences between Navigator CM and YSI are calculated in whole number differences in the units of insulin. This seemingly arbitrary choice of the hypothetical patient has no influence on the results of the Insulin Adjustment Analysis—the choice was based on the goals of intensive insulin therapy and the ease of interpretation of the results.


The Insulin Adjustment Analysis data is reported as differences in units of insulin. (see Table 4). This is an intermediate result that allows a more detailed characterization of the data than the final summary (see Table 5). Decisions with Navigator CM were rated Correct 89.3% (1180/1322) of the time and Acceptable 7.6% (100/1322) of the time. Since the Acceptable rating translates to a glucose adjustment to within the normal glucose range, accurate adjustments are the sum of Correct and Acceptable categories, 96.8% (1280/1322).









TABLE 4







Treatment Difference for the Hypothetical Patient with Insulin


Sensitivity = 30 mg/dL/unit and Glucose Target = 90-120 mg/dL









Navigator CM-




YSI Treatment


Difference
Glucose <200 mg/dL
Glucose ≧200 mg/dL













(Units of insulin)
N
%
Category
N
%
Category
















−4  
0
0
Hyperglycemia 2
4
0.6
Hyperglycemia 2


−3  
1
0.1
Hyperglycemia 1
13
2.0
Hyperglycemia 1


−2  
11
1.6
Acceptable
78
12.1
Acceptable


−1  
120
17.7
Correct
215
33.4
Correct


0
353
52.0
Correct
240
37.3
Correct


1
173
25.5
Correct
79
12.3
Correct


2
18
2.7
Possible Error
11
1.7
Acceptable


3
2
0.3
Error
3
0.5
Possible Error


4
1
0.1
Error
0
0
Error


Total
679
100

643
100
















TABLE 5







Insulin Adjustment Analysis Summary










Category
Effect on Blood Glucose
N
%













Correct
Within ±30 mg/dL of target
1180
89.3



glucose


Acceptable
Within normal glucose range
100
7.6


Possible Error (hypo)
60 mg/dL below target glucose
21
1.6


Error (hypo)
≧90 mg/dl below target glucose
3
0.2


Hyperglycemia 1
90 mg/dL above target glucose
14
1.1


Hyperglycemia 2
≧120 mg/dl above target glucose
4
0.3


Total

1322
100









In summary, this analysis describes 3 occurrences of “Error (hypo)” and 4 occurrences of “hyperglycemia 2” being potentially indicated from 1322 decision points analyzed.


Glucose Peak


Continuous glucose monitoring provides the ability to identify and quantify the maximum glucose excursions after meals and during the night. The quantification of glucose peaks was clinically accurate 88.1% of the time and clinically useful 97.6% of the time (see Table 6).









TABLE 6







Glucose Peak Analysis










Difference
Clinical Assessment
N
%













±15 mg/dL
Accurate
263
41.5


±45 mg/dL
Accurate
295
46.6


±75 mg/dL
Useful
60
9.5


±105 mg/dL 
Misclassification
14
2.2


±135 mg/dL 
Misclassification
1
0.2


Total

633
100.0










Insulin Adjustment Analysis


The Insulin Adjustment Analysis evaluates the hypothetical difference between insulin dosing based on Navigator CM readings to that based on a blood glucose meter such as Freestyle Blood Glucose (BG) readings. The interpretation of the analysis is best understood considering a hypothetical patient with a glucose target level of 90-120 mg/dL and an insulin sensitivity of 30 mg/dL/unit. The glucose target level represents aggressive therapy where the therapeutic goal is to keep glucose squarely in the normal range. The analysis is targeted to meet the requirements of intensive insulin therapy. The choice of insulin sensitivity was made to simplify interpretation—the treatment differences between Navigator CM and Freestyle BG YSI (see Table 7) are calculated in whole number differences in the units of insulin. This seemingly arbitrary choice of the hypothetical patient has no influence on the results of the Insulin Adjustment Analysis—the choice was based the goals of intensive insulin therapy and the ease of interpretation of the results.


The Insulin Adjustment Analysis data is reported as differences in units of insulin (see Table 7). There were 6,040 paired (Navigator CM-Freestyle BG) glucose readings available at times of subject-reported insulin dosing or bedtime in the Home Use Study. The analysis is summarized in Table 8 with 86.5% (5226/6040) of the readings correct and 94.3% (5696/6040) accurate or acceptable. These results provide approximately 89.3% (1180/1322) correct and 96.8% (1280/1322) accurate or acceptable.









TABLE 7







Treatment Difference for the Hypothetical Patient


with Insulin Sensitivity = 30 mg/dL/


unit and Glucose Target = 90-120 mg/dL









Difference




in Insulin
Glucose < 200 mg/dL
Glucose ≧ 200 mg/dL











Dose (Units)
N
(%)
N
(%)














4
0
0
1
0.0


3
11
0.3
2
0.1


2
84
2.1
14
0.7


1
810
20.1
162
8.1


0
2362
58.5
530
26.5


−1
675
16.7
687
34.3


−2
89
2.2
367
18.3


−3
8
0.2
163
8.1


−4
0
0
75
3.7


Total
4039

2001

















TABLE 8







Insulin Adjustment Analysis Summary










Category
Effect on Blood Glucose
N
%













Correct
Within ±30 mg/dL of target
5226
86.5



glucose


Acceptable
Within normal glucose range
470
7.8


Possible Error
60 mg/dL below target glucose
86
1.4


(hypo)


Error (hypo)
≧90 mg/dl below target
12
0.2



glucose


Hyperglycemia 1
90 mg/dL above target glucose
171
2.8


Hyperglycemia 2
≧120 mg/dl above target
75
1.2



glucose



Total

6040
100









Insulin dosing or bedtime was not indicated for 5,447 of the 11,487 Freestyle BG duplicate points. The Insulin Adjustment Analysis was also conducted using the 5,447 Freestyle BG duplicate points for which there was no indication of insulin injection to determine if there was a substantive difference between the two populations. The Insulin Adjustment Analysis data is reported as differences in units of insulin (See Table 9). The results are slightly better for the points where insulin injections were not indicated (See Table 10) with 89.4% (4868/5447) correct and 95.5 (5203/5447) correct or acceptable.









TABLE 9







Treatment Difference for the Hypothetical Patient with


Insulin Sensitivity = 30 mg/dL/unit and


Glucose Target = 90-120 mg/dL - Non-insulin Injection Points









Difference




in Insulin
Glucose < 200 mg/dL
Glucose ≧ 200 mg/dL











Dose (Units)
N
(%)
N
(%)














4
2
0.0
0
0


3
11
0.3
1
0.1


2
95
2.3
26
2.0


1
876
21.2
132
10.0


0
2473
59.9
388
29.5


−1
588
14.2
411
31.2


−2
81
2.0
228
17.3


−3
5
0.1
88
6.7


−4
0
0
42
3.2


Total
4131

1316

















TABLE 10







Insulin Adjustment Analysis Summary


Non-insulin Injection Points










Category
Effect on Blood Glucose
N
%













Correct
Within ±30 mg/dL of target
4868
89.4



glucose


Acceptable
Within normal glucose range
335
6.2


Possible Error
60 mg/dL below target glucose
96
1.8


(hypo)


Error (hypo)
≧90 mg/dl below target glucose
13
0.2


Hyperglycemia 1
90 mg/dL above target glucose
93
1.7


Hyperglycemia 2
≧120 mg/dl above target glucose
42
0.8


Total

5447
100









When a patient adjusts an insulin dose using a blood glucose meter such as Freestyle Blood Glucose monitor, there is no indication if glucose is changing. If glucose is rising at the time of glucose dosing, there is insufficient insulin to stabilize blood glucose and the predicted insulin dose will be too small. Likewise, if glucose is descending, there is already insulin in the blood, and the predicted insulin dose will be too large. The rate of glucose change indicated by Navigator CM at the time of insulin dosing (see Table 11) indicates glucose changes >±2 mg/dL/minute 4.0% of the time, and >±1 mg/dL/minute 18.3% of the time. The agreement of static the blood glucose meter readings with static reference readings is excellent, but the interpretation of this agreement to suggest accurate insulin dosing with the blood glucose meter is not correct. When insulin is dosed with no knowledge of changing glucose levels, the dosing will be incorrect a significant fraction of the time. The determination of 94.3% Navigator CM dosing accuracy in this study and 96.8% Navigator CM dosing accuracy in a previous study provide realistic estimations when the rate of glucose change is also known.









TABLE 11







Navigator CM Rate Indication at the Time of Insulin Dosing









Navigator CM Rate of Change (mg/dL/minute)
N
(%)












>2.0
330
3.3


1.0 to 2.0
897
9.0


−1.0 to 1.0  
8140
81.7


−2.0 to −1.0
526
5.3


<−2.0
72
0.7









The description below details a further user study results from a highly accurate continuous glucose monitoring system such as, for example, Freestyle Navigator® system. Of the 137 subjects enrolled in the investigation, 123 completed the 40-day monitoring period. The other 14 subjects withdrew from the study due to non-compliance with protocol demands (n=8) or difficulties handling the device (n=6). None of the discontinued subjects participated in the unblinded portion of the study. The glucose data available for the discontinued subjects was included in the paired point analysis.


The performance of the Freestyle Navigator® was assessed using the absolute relative difference between the sensor interstitial glucose measurements and the blood glucose measurements. Data from 961 sensors with 11,487 paired FreeStyle BG reference values were evaluated. The mean absolute relative difference was 14.4% and the median absolute relative difference was 11.1%. The mean absolute relative difference indicates that, on average, the CM reading was 14.4% higher or lower than the corresponding BG reading. The median absolute relative difference indicates that the CM reading was equally as likely to be within 11.1% of the BG reading, either higher or lower, as it was to be outside of that range.


The equation for the Deming regression had a slope of 0.83, an intercept of 21.8 mg/dL and correlation coefficient of 0.92. These results demonstrate a strong correlation between CM and BG readings.



FIG. 7 shows the Clarke error grid for the study. There were a total of 11,487 paired points with averaged duplicate BG reference values and interpolated CM values, from 131 subjects. No paired points were available from six subjects. Of the 11,487 paired points, 77.2% fell in the Clarke error grid zone A, indicating a high level of correspondence between the reference blood glucose measurements and the CM results. There were 19.6% of the paired points in zone B and only 3.2% outside the A and B zones. Results for all the Clarke error grid zones are shown in Table 12 below. The results of the Consensus error grid are also included in Table 12.









TABLE 12







Summary statistics of Clarke and Consensus Error Grid












Clarke Error

Consensus




Grid

Error Grid











Zone
N
(%)
N
(%)














A
8863
77.2
9180
79.9


B
2255
19.6
2194
19.1


C
1
0.0
109
0.9


D
365
3.2
4
0.0


E
3
0.0
0
0.0


N paired points
11487

11487









On the Clarke error grid, there were 365 individual points in the D zone. On the Consensus error grid, by contrast, the number of points in the D zone is reduced to four. In addition, the Consensus error grid shows 79.9% in the A zone, 99.0% in the A and B zones, less than 1% in the C and D zones and no points in the E zone.


A comparison of accuracy and performance by day of sensor wear shows that the system's performance on the fifth day is nearly equivalent to the performance on the first or second day. Table 13 contains data with the error grid statistics as well as the mean absolute relative difference from the study separated by day.









TABLE 13







Clarke Error Grid, absolute relative difference by day













Day 1
Day 2
Day 3
Day 4
Day 5


Zone
N/(%)
N/(%)
N/(%)
N/(%)
N/(%)




















Clarke A
1061
(77.8)
2182
(77.4)
2110
(77.7)
1884
(79.3)
1626
(73.5)


Clarke B
266
(19.5)
551
(19.6)
516
(19.0)
427
(18.0)
495
(22.4)


Clarke C
0
(0.0)
0
(0.0)
0
(0.0)
0
(0.0)
1
(0.0)


Clarke D
36
(2.6)
84
(3.0)
91
(3.3)
63
(2.7)
91
(4.1)


Clarke E
1
(0.1)
1
(0.0)
0
(0.0)
1
(0.0)
0
(0.0)


N paired
1364

2818

2717

2375

2213


points


Consensus A


Consensus B


Consensus C


Consensus D


Consensus E


N paired
1364

2818

2717

2375

2213


points


Mean
14.8

14.3

14.0

13.9

15.3


ARD


Median


ARD









Table 14 shows that the CM readings are optimal when blood glucose is relatively stable (i.e., when the rate is within +/−1 mg/dL/min). As expected the bias increases somewhat as the magnitude of the rate of glucose change increases. However, the displayed rate arrow provides the necessary information to properly interpret the glucose result in these situations. The mean bias for glucose <100 mg/dL and the mean percent bias for glucose ≧100 mg/dL become increasingly positive as the rate decreases from +2 mg/dL/minute to −2 mg/dL/minute. Lag in the interstitial readings versus capillary blood glucose readings is the explanation for this result. When glucose levels were rising, the CM values were low, on average, versus BG with the difference versus BG lower for rising glucose (>1 mg/dL/minute) than for stable glucose (±1 mg/dL/minute). When glucose levels were falling CM was high, on average, versus BG with the difference versus BG higher for falling glucose (<1 mg/dL/minute) than for stable glucose (±1 mg/dL/minute).









TABLE 14







Difference measures vs. glucose rate of change












Navigator CM Rate of Change






(mg/dL per minute)
Mean
Median
N











Difference (mg/dL) for glucose <100 mg/dL












>2.0
3.7
−1.2
3



1.0 to 2.0
4.7
5.5
33



−1.0 to 1.0  
7.6
7.1
2028



−2.0 to −1.0
17.9
18.7
261



<−2.0
26.5
24.4
50







Absolute difference (mg/dL) for glucose <100 mg/dL












>2.0
11.0
9.8
3



1.0 to 2.0
12.5
9.9
33



−1.0 to 1.0  
13.3
10.8
2028



−2.0 to −1.0
21.5
19.4
261



<−2.0
32.4
27.0
50







Percent difference % for glucose ≧=100 mg/dL












>2.0
−13.7
−14.3
152



1.0 to 2.0
−10.9
−10.7
581



−1.0 to 1.0  
−3.5
−3.7
7245



−2.0 to −1.0
6.9
6.8
432



<−2.0
7.5
9.1
69







Absolute % difference % for glucose ≧=100 mg/dL












>2.0
17.0
16.1
152



1.0 to 2.0
14.8
12.6
581



−1.0 to 1.0  
12.2
9.8
7274



−2.0 to −1.0
15.9
12.6
432



<−2.0
18.3
14.5
69










The Clarke EGA as a function of Navigator rate (Table 15) exhibits the expected behavior. When glucose is descending by at least −2 mg/dL/min, there is a higher likelihood that a reading would fall into the left Zone D than when the glucose is stable or rising. When glucose is rising, there is a higher likelihood that a reading would fall into the right Zone D. The rate arrow provides the valuable information to properly interpret the glucose result (i.e. when glucose is rapidly descending Navigator CM tends to be higher than Navigator BG and when glucose is rapidly ascending Navigator CM tends to be lower than Navigator BG).









TABLE 15







Clarke EGA vs. glucose rate of change

















Zone
<−2.0
%
−2.0 to −1.0
%
−1.0 to 1.0
%
1.0 to 2.0
%
>2.0
%




















A
61
51.3
425
61.3
7372
79.3
455
74.1
101
65.2


B
45
37.8
194
28.0
1688
18.1
149
24.3
48
31.0


C
0
0.0
1
0.1
0
0.0
0
0.0
0
0.0


D
12
10.1
73
10.5
240
2.6
10
1.6
6
3.9


E
1
0.8
0
0.0
2
0.0
0
0.0
0
0.0


Total
119

692

9302

614

155










Sensor Success Measures


The rate of successful sensor insertions was evaluated from reported results of each sensor insertion attempt, as well as the electronic records stored by the Receiver. The electronic records were used to determine whether each sensor was detected by the Receiver, and whether the user followed the steps in the labeling. The percentage of insertions that were successful, when used as directed, was similar for the blinded (96.0%) and unblinded (96.8%) phases of the study (96.4% overall). The percentage of successful insertions was similar for the arm (95.7%) and abdomen (97.4%) insertion sites. Abdomen insertions may have been more successful because it is easier to see the entire insertion process at the abdomen site when inserting a sensor on oneself.


The success rate for the initial Sensor Calibration process was evaluated from results recorded in the receiver log data for each successful sensor insertion attempt. The time required to complete the first sensor calibration was evaluated in addition to the overall success or failure. The percentage of sensors that were successfully calibrated and produced glucose results within the first 12 hours was calculated. Sensor calibration is not allowed within the first 10 hours. Sensors that could not be calibrated because conditions were out of range were excluded, e.g., if the glucose was changing too rapidly for calibration. The percentage of sensors that were successfully calibrated within 12 hours, when used as directed, was similar for the blinded (90.5%) and unblinded (92.6%) phases of the study (91.5% overall).


Sensor duration was evaluated as the time duration from sensor insertion to the last CM glucose result reported for the sensor. Some sensors were removed early by user error or discretion, or because of protocol logistics such as the end of the trial. These sensors are excluded from analysis, unless the sensor reached the nominal 5-day sensor life (>108 hours). The median sensor life was similar for the blinded (119.9 hours) and unblinded (120.0 hours) phases of the study. The percentage of sensors, used as directed, that produced glucose results for 108 hours or more was similar for the blinded (83.5%) and unblinded (83.0%) phases of the study. Sensors on the arm tended to have slightly longer duration (86.2% for >108 hours) than those on the abdomen (79.4%), because there is somewhat less flexing and folding of the skin at the posterior arm insertion site than on the abdomen, improving the effectiveness of the skin adhesive that holds the sensor in place.


Glycemic Analysis


The change in glycemic status between the blinded and unblinded phases of the study was stratified by type 1 and type 2 diabetes. During the unblinded phase when alarms were set, subjects were instructed to perform a BG test when alarms were triggered. Some important differences in controlling glucose concentration with insulin administration between the two types of diabetes are the following:

    • Subjects with type 2 diabetes are less likely to induce hypoglycemia with insulin because they are insensitive to insulin. Type 1 subjects, with normal insulin sensitivity are much more likely to induce hypoglycemia.
    • Subjects with type 2 diabetes can reduce hyperglycemia by reducing carbohydrate ingestion and allowing endogenous insulin to reduce blood glucose. Patients with type 1 diabetes produce no endogenous insulin, so a reduction of carbohydrates is not a viable strategy for controlling glucose. Controlling glucose with injected insulin is much more difficult than control with endogenous insulin.


The time spent in hypoglycemic (<70 mg/dL), euglycemic (70-180 mg/dL) and hyperglycemic ranges is illustrated in FIG. 8 for type 1 and 2 subjects in the blinded and unblinded phases of the study.


The type 1 subjects improved in the unblinded phase by reducing time in hypoglycemia. The time spent below the 70 mg/dL threshold for hypoglycemia was reduced by 42% from 1.4 hours to 0.8 hours (p<0.0001). The time spent in hyperglycemia (>180 mg/dL) did not change.


For type 2 subjects, the duration of hyperglycemia improved in the unblinded phase. The time spent in the euglycemic range increased by 12% (p=0.0027) and the time spent >180 mg/dL decreased by 18% (p=0.0057). As anticipated, the measures of hypoglycemia for type 2 subjects, which were low in the blinded phase, were largely unchanged in the unblinded phase.


Accordingly, a continuous analyte monitoring system in one embodiment includes an analyte sensor having at least about 80% of its paired data points within zone A and at least about 95% of its paired data points within zone A and zone B of the Clarke Error Grid, a transmitter capable of receiving information from the sensor, and a receiver capable of receiving information from the transmitter.


In one aspect, analyte sensor has at least about 85% of its paired data points within zone A of the Clarke Error Grid.


In a further aspect, the analyte sensor has at least about 90% of its paired data points within zone A of the Clarke Error Grid.


In still a further aspect, the analyte sensor has more than approximately 90% of its paired data points within zone A of the Clarke Error Grid.


Additionally, in another aspect, the analyte sensor has at least about 85% of its paired data points within zone A of the Consensus Error Grid, and further, where the analyte sensor has at least about 90% of its paired data points within zone A of the Continuous Glucose Error Grid Analysis.


The analyte sensor may be a glucose sensor.


In yet another aspect, the system may not require confirmation of analyte data obtained by the system.


The system may include a drug delivery device, where one or more of the transmitter and the receiver may be adapted to transmit analyte information to the drug delivery device.


In another aspect, the analyte sensor may be calibrated using single point calibration.


A continuous analyte monitoring system in accordance with another embodiment includes an analyte sensor having at least about 85% of its paired data points within zone A and at least about 95% of its paired data points within zone A and zone B of the Consensus Error Grid, a transmitter capable of receiving information from the sensor, and a receiver capable of receiving information from the transmitter.


The analyte sensor may have at least about 85% of its paired data points within zone A of the Consensus Error Grid.


The analyte sensor may have at least about 90% of its paired data points within zone A of the Consensus Error Grid.


The analyte sensor may have more than approximately 90% of its paired data points within zone A of the Consensus Error Grid.


In another aspect, the system may not require confirmation of analyte data obtained by the system.


The system may include a drug delivery device, where one or more of the transmitter and the receiver may be adapted to transmit analyte information to the drug delivery device.


Also, the analyte sensor may be calibrated using single point calibration.


A method of monitoring glucose levels in accordance with still another embodiment includes determining glucose concentration using a first transcutaneously positioned analyte sensor, reporting glucose concentration to a user, where a second sensor is not used to confirm the accuracy of the first transcutaneously positioned analyte sensor.


In one aspect, determining may include over a period of time ranging from about 1 day to about 7 days.


The first transcutaneously positioned analyte sensor may have at least about 85% of its paired data points within zone A of the Clarke Error Grid.


The first transcutaneously positioned analyte sensor may have at least about 90% of its paired data points within zone A of the Clarke Error Grid.


The first transcutaneously positioned analyte sensor may have more than about 90% of its paired data points within zone A of the Clarke Error Grid.


The first transcutaneously positioned analyte sensor may be a glucose sensor.


The method in a further aspect may include determining health related information based on the reported glucose concentration, where the health related information may include a bolus amount, or one or more of a food intake, medication dosage level, or activity level.


Also, the medication dosage level may include insulin dosage level.


In a further aspect, the method may include transmitting the reported glucose concentration, and where transmitting may include one or more of a wired transmission or a wireless transmission.


In still another aspect, the method may include calibrating the first transcutaneously positioned analyte sensor using single point calibration.


The first transcutaneously positioned analyte sensor may have at least about 95% of its paired data points within zone A and zone B of the Clarke Error Grid.


The first sensor may have at least about 85% of its paired data points within zone A.


A method of monitoring glucose levels in accordance with yet another embodiment includes determining glucose concentration using a first transcutaneously positioned analyte sensor, reporting glucose concentration to a user, where accuracy of the first transcutaneously positioned analyte sensor is established other than with a second sensor.


In one aspect, the first transcutaneously positioned analyte sensor has at least about 85% of its paired data points within zone A of the Clarke Error Grid.


In another aspect, the first transcutaneously positioned analyte sensor has at least about 90% of its paired data points within zone A of the Clarke Error Grid.


In still another aspect, the first transcutaneously positioned analyte sensor has more than about 90% of its paired data points within zone A of the Clarke Error Grid.


The first transcutaneously positioned analyte sensor may be a glucose sensor.


A method of monitoring glucose levels using a single glucose sensor in accordance with still yet a further embodiment includes transcutaneously positioning a glucose sensor in a patient for a period of time, determining glucose concentration of the patient using the transcutaneously positioned glucose sensor, and using one or more additional devices during the period of time only to calibrate the glucose sensor but not to confirm the accuracy of the transcutaneously positioned glucose sensor.


The glucose sensor in one embodiment has at least about 85% of its paired data points within zone A and at least about 95% of its paired data points within zone A and zone B of the Clarke Error Grid.


The glucose concentration may be determined over a period of time ranging from about 1 day to about 7 days.


In a further aspect, the glucose sensor has at least about 85% of its paired data points within zone A of the Clarke Error Grid.


In yet another aspect, the glucose sensor has at least about 90% of its paired data points within zone A of the Clarke Error Grid.


The glucose sensor in still another aspect has more than approximately 90% of its paired data points within zone A of the Clarke Error Grid.


In still a further aspect, the method may include determining a health related information based on the determined glucose concentration, where the health related information includes one or more of a food intake, medication dosage level, or activity level, and further, where medication dosage level includes insulin dosage level.


The method may include transmitting data associated with the determined glucose concentration, where transmitting may include one or more of a wired transmission or a wireless transmission.


Also, calibration of the glucose sensor may include performing single point calibration.


An analyte monitoring system in accordance with still yet another embodiment includes an analyte sensor configured to detect one or more analyte levels of a patient, a transmitter unit operatively coupled to the analyte sensor, the transmitter unit configured to transmit one or more signals associated with the detected one or more analyte levels, and a receiver unit configured to receive the transmitted one or more signals associated with the detected one or more analyte levels, where the accuracy of the detected one or more analyte levels relied upon to make a clinically relevant decision is established without using a blood glucose measurement.


In one aspect, the clinically relevant decision may include healthcare decision.


The clinically relevant decision may include a bolus amount determination.


The blood glucose measurement may include a confirmatory blood glucose measurement.


The detected one or more analyte level may be calibrated, for example, using single point calibration.


The transmitter unit may be configured to wirelessly transmit the one or more signals to the receiver unit.


The analyte sensor in one embodiment has at least about 85% of its paired data points within zone A and at least about 95% of its paired data points within zone A and zone B of the Clarke Error Grid.


An analyte monitoring device in accordance with still yet a further embodiment includes a receiver unit for receiving one or more signals related to an analyte level detected by an electrochemical sensor, the receiver unit including a display to display an indication of the analyte level, where the electrochemical sensor has at least about 85% of its paired data points within zone A and at least about 95% of its paired data points within zone A and zone B of the Clarke Error Grid.


The electrochemical sensor may have at least about 85% of its paired data points within zone A of the Clarke Error Grid.


The electrochemical sensor may have at least about 90% of its paired data points within zone A of the Clarke Error Grid.


The electrochemical sensor may have more than approximately 90% of its paired data points within zone A of the Consensus Error Grid.


The receiver unit may be configured to calibrate the one or more signals related to the analyte level, and further, where the receiver unit may be configured to display the calibrated one or more signals related to the analyte level without a confirmatory blood glucose measurement.


In another aspect, the receiver unit may be configured to calibrate the one or more signals related to the analyte level using single point calibration.


The receiver unit may be configured to display the one or more signals related to the analyte level without a confirmatory blood glucose measurement.


The receiver unit in one embodiment may include one of an rf receiver or an rf transceiver.


The receiver unit in still a further aspect may be configured to calibrate the one or more signals related to the analyte level using a calibration value of less that about one microliter of body fluid, where the body fluid includes blood.


The receiver unit may include an alarm configured to indicate when the analyte level is at or near a threshold level.


The threshold level may include one of hypoglycemia, impending hypoglycemia, hyperglycemia, or impending hyperglycemia.


The alarm may include one or more of an audible signal, a visual display, or a vibratory signal.


The alarm may be configured to automatically deactivate after a predetermined time period.


The receiver unit in one aspect may be a portable handheld unit.


The receiver unit may be configured for wearing on or under an article of clothing.


The receiver unit may include an rf transceiver configured to receive or transmit the one or more signals related to an analyte level.


In still another aspect, the display may be configured to display one or more of analyte level trend information, rate of change information associated with the analyte level, basal profile information, bolus amount information, or therapy related information.


In a further aspect, the receiver may include a blood glucose meter.


The display may be configured to display the indication of the analyte level at least one or more of once per minute, once per five minutes, once per ten minutes, or over a predetermined time period, where the predetermined time period may include one or more of less than 24 hour period, one day, three days, seven days, fourteen days, twenty one days, twenty eight days, less than thirty days, or greater than thirty days.


A monitoring device in a further embodiment includes a portable housing, an rf receiver coupled to the portable housing, the rf receiver configured to wirelessly receive one or more signals related to an analyte level of a patient detected by an electrochemical sensor, a processing unit coupled to the portable housing and to the rf receiver, the processing unit configured to process the one or more signal received by the rf receiver, and a display unit coupled to the portable housing and the processing unit, the display unit configured to display an indication associated with the one or more signals related to the analyte level of the patient, where the electrochemical sensor has at least about 85% of its paired data points within zone A and at least about 95% of its paired data points within zone A and zone B of the Consensus Error Grid.


The electrochemical sensor may have at least about 85% of its paired data points within zone A of the Consensus Error Grid.


The electrochemical sensor may have at least about 90% of its paired data points within zone A of the Consensus Error Grid.


An analyte monitoring device in accordance with still another embodiment includes a receiver unit for receiving one or more signals related to an analyte level detected by an electrochemical sensor, the receiver unit including a display to display an indication of the analyte level, and the receiver unit further configured to process one or more signals related to analyte related therapy for communication with a drug administration system, where the electrochemical sensor has at least about 85% of its paired data points within zone A and at least about 95% of its paired data points within zone A and zone B of the Clarke Error Grid.


In one aspect, the electrochemical sensor has at least about 90% of its paired data points within zone A of the Clarke Error Grid.


Various other modifications and alterations in the structure and method of operation of this disclosure will be apparent to those skilled in the art without departing from the scope and spirit of the present disclosure. Although the present disclosure has been described in connection with specific embodiments, it should be understood that the embodiments of the present disclosure as claimed should not be unduly limited to such specific embodiments. It is intended that the following claims define the scope of the present disclosure and that structures and methods within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. An analyte monitoring device, comprising: a receiver unit for receiving one or more signals related to an analyte level detected by an electrochemical sensor, the receiver unit including a display to display an indication of the analyte level, wherein the electrochemical sensor includes a portion transcutaneously positioned under a skin surface and in fluid contact with an interstitial fluid to continuously monitor the analyte level over a predetermined time period and to detect the one or more signals related to the analyte level; and furtherwherein the receiver unit includes a signal processing algorithm to process the received one or more signals and to display the indication of the analyte level over the predetermined time period without confirming the accuracy level of the received one or more signals detected by the electrochemical sensor using an adjunctive measurement, wherein the received one or more signals from the electrochemical sensor has a Clarke Error Grid accuracy and a Consensus Error Grid accuracy of at least 80% within zone A and zone B.
  • 2. The device of claim 1, wherein the accuracy level of the received one or more signals detected by the electrochemical sensor is determined to be clinically accurate based on the Clarke Error Grid.
  • 3. The device of claim 1, wherein the accuracy level of the received one or more signals detected by the electrochemical sensor is determined to be clinically accurate based on the Consensus Error Grid.
  • 4. The device of claim 1 wherein the receiver unit is configured to calibrate the one or more signals related to the analyte level.
  • 5. The device of claim 4 wherein the receiver unit is configured to display the calibrated one or more signals related to the analyte level without a confirmatory blood glucose measurement.
  • 6. The device of claim 1 wherein the receiver unit is configured to calibrate the one or more signals related to the analyte level using single point calibration.
  • 7. The device of claim 1 wherein the receiver unit is configured to display the one or more signals related to the analyte level without a confirmatory blood glucose measurement.
  • 8. The device of claim 1 wherein the receiver unit includes one of an rf receiver or an rf transceiver.
  • 9. The device of claim 1 wherein the receiver unit is configured to calibrate the one or more signals related to the analyte level using a calibration value of less that about one microliter of body fluid.
  • 10. The device of claim 9 wherein the body fluid includes blood.
  • 11. The device of claim 1 wherein the receiver unit includes an alarm configured to indicate when the analyte level is at or near a threshold level.
  • 12. The device of claim 11 wherein the threshold level includes one of hypoglycemia, impending hypoglycemia, hyperglycemia, or impending hyperglycemia.
  • 13. The device of claim 11 wherein the alarm includes one or more of an audible signal, a visual display, or a vibratory signal.
  • 14. The device of claim 11 wherein the alarm is configured to automatically deactivate after a predetermined time period.
  • 15. The device of claim 1 wherein the receiver unit is a portable handheld unit.
  • 16. The device of claim 15 wherein the receiver unit is configured for wearing on or under an article of clothing.
  • 17. The device of claim 1 wherein the receiver unit includes an rf transceiver configured to receive or transmit the one or more signals related to an analyte level.
  • 18. The device of claim 1 wherein the display is configured to display one or more of analyte level trend information, rate of change information associated with the analyte level, basal profile information, bolus amount information, or therapy related information.
  • 19. The device of claim 1 including a blood glucose meter.
  • 20. The device of claim 1 wherein the display is configured to display the indication of the analyte level at least one or more of once per minute, once per five minutes, once per ten minutes, or over a predetermined time period.
  • 21. The device of claim 20 wherein the predetermined time period includes one or more of less than 24 hour period, one day, three days, seven days, fourteen days, twenty one days, twenty eight days, less than thirty days, or greater than thirty days.
  • 22. An analyte monitoring device, comprising: a receiver unit for receiving one or more signals related to an analyte level detected by an electrochemical sensor, the receiver unit including a display to display an indication of the analyte level, and the receiver unit further configured to process one or more signals related to analyte related therapy for communication with a drug administration system; wherein the electrochemical sensor includes a portion transcutaneously positioned under a skin surface and in fluid contact with an interstitial fluid to continuously monitor the analyte level over a predetermined time period and to detect the one or more signals related to the analyte level; and furtherwherein the receiver unit includes a signal processing algorithm to process the received one or more signals and to display the indication of the analyte level over the predetermined time period without confirming the accuracy level of the received one or more signals detected by the electrochemical sensor using an adjunctive measurement, wherein the received one or more signals from the electrochemical sensor has a Clarke Error Grid accuracy and a Consensus Error Grid accuracy of at least 80% within zone A and zone B.
  • 23. The device of claim 22, wherein the accuracy level of the received one or more signals detected by the electrochemical sensor is determined to be clinically accurate based on the Clarke Error Grid.
RELATED APPLICATIONS

This application claims priority under 35 USC §119 to Provisional Application No. 60/804,170 filed Jun. 7, 2006 entitled “Analyte Monitoring”, and to Provisional Application No. 60/804,169 filed Jun. 7, 2006 entitled “Analyte Monitoring System” the disclosure of each of which are incorporated in their entirety by reference for all purposes

US Referenced Citations (2118)
Number Name Date Kind
2402306 Turkel Jun 1946 A
3132123 Harris, Jr. et al. May 1964 A
3210578 Sherer Oct 1965 A
3219533 Mullins Nov 1965 A
3260656 Ross, Jr. Jul 1966 A
3282875 Connolly et al. Nov 1966 A
3304413 Lehmann et al. Feb 1967 A
3310606 Fritz Mar 1967 A
3381371 Russell May 1968 A
3397191 Beckerbauer Aug 1968 A
3581062 Aston May 1971 A
3635926 Gresham et al. Jan 1972 A
3651318 Czekajewski Mar 1972 A
3653841 Klein Apr 1972 A
3698386 Fried Oct 1972 A
3719564 Lilly, Jr. et al. Mar 1973 A
3768014 Smith et al. Oct 1973 A
3775182 Patton et al. Nov 1973 A
3776832 Oswin et al. Dec 1973 A
3785939 Hsu Jan 1974 A
3826244 Salcman et al. Jul 1974 A
3837339 Aisenberg et al. Sep 1974 A
3851018 Kelly Nov 1974 A
3898984 Mandel et al. Aug 1975 A
3919051 Koch et al. Nov 1975 A
3926760 Allen et al. Dec 1975 A
3929971 Roy Dec 1975 A
3930889 Ruggiero et al. Jan 1976 A
3933593 Sternberg Jan 1976 A
3943918 Lewis Mar 1976 A
3949388 Fuller Apr 1976 A
3957613 Macur May 1976 A
3964974 Banauch et al. Jun 1976 A
3966580 Janata et al. Jun 1976 A
3972320 Kalman Aug 1976 A
3979274 Newman Sep 1976 A
4008717 Kowarski Feb 1977 A
4016866 Lawton Apr 1977 A
4024312 Korpman May 1977 A
4032729 Koistinen Jun 1977 A
4036749 Anderson Jul 1977 A
4040908 Clark, Jr. Aug 1977 A
4052754 Homsy Oct 1977 A
4055175 Clemens et al. Oct 1977 A
4059406 Fleet Nov 1977 A
4059708 Heiss, Jr. et al. Nov 1977 A
4073713 Newman Feb 1978 A
4076596 Connery et al. Feb 1978 A
4076656 White et al. Feb 1978 A
4098574 Dappen Jul 1978 A
4100048 Pompei et al. Jul 1978 A
4120292 LeBlanc, Jr. et al. Oct 1978 A
4129128 McFarlane Dec 1978 A
4146029 Ellinwood, Jr. Mar 1979 A
4151845 Clemens May 1979 A
4154231 Russell May 1979 A
4168205 Danniger et al. Sep 1979 A
4172770 Semersky et al. Oct 1979 A
4178916 McNamara Dec 1979 A
4193982 Avrameas et al. Mar 1980 A
4197840 Beck et al. Apr 1980 A
4206755 Klein Jun 1980 A
4215703 Willson Aug 1980 A
4224125 Nakamura et al. Sep 1980 A
4240438 Updike et al. Dec 1980 A
4240889 Yoda et al. Dec 1980 A
4241438 Kern Dec 1980 A
4245634 Albisser et al. Jan 1981 A
4247297 Berti et al. Jan 1981 A
4253469 Aslan Mar 1981 A
4255500 Hooke Mar 1981 A
4259540 Sabia Mar 1981 A
4271449 Grogan Jun 1981 A
4275225 Krespan Jun 1981 A
4282872 Franetzki et al. Aug 1981 A
4294258 Bernard Oct 1981 A
4318784 Higgins et al. Mar 1982 A
4324257 Albarda et al. Apr 1982 A
4327725 Cortese et al. May 1982 A
4331869 Rollo May 1982 A
4335255 Krespan Jun 1982 A
4340458 Lerner et al. Jul 1982 A
4344438 Schultz Aug 1982 A
4345603 Schulman Aug 1982 A
4349728 Phillips et al. Sep 1982 A
4352960 Dormer et al. Oct 1982 A
4353888 Sefton Oct 1982 A
4356074 Johnson Oct 1982 A
4357282 Anderson et al. Nov 1982 A
4360019 Portner et al. Nov 1982 A
4365637 Johnson Dec 1982 A
4366033 Richter et al. Dec 1982 A
4374013 Enfors Feb 1983 A
4375399 Havas et al. Mar 1983 A
4384586 Christiansen May 1983 A
4388166 Suzuki et al. Jun 1983 A
4390621 Bauer Jun 1983 A
4392933 Nakamura et al. Jul 1983 A
4401122 Clark, Jr. Aug 1983 A
4403984 Ash et al. Sep 1983 A
4404066 Johnson Sep 1983 A
4407288 Langer et al. Oct 1983 A
4407959 Tsuji et al. Oct 1983 A
4415666 D'Orazio et al. Nov 1983 A
4417588 Houghton et al. Nov 1983 A
4418148 Oberhardt Nov 1983 A
4420564 Tsuji et al. Dec 1983 A
4425920 Bourland et al. Jan 1984 A
4427004 Miller et al. Jan 1984 A
4427770 Chen et al. Jan 1984 A
4431004 Bessman et al. Feb 1984 A
4431507 Nankai et al. Feb 1984 A
4436094 Cerami Mar 1984 A
4440175 Wilkins Apr 1984 A
4442841 Uehara et al. Apr 1984 A
4443218 DeCant, Jr. et al. Apr 1984 A
4444892 Malmros Apr 1984 A
4450842 Zick et al. May 1984 A
4458686 Clark, Jr. Jul 1984 A
4461691 Frank Jul 1984 A
4467811 Clark, Jr. Aug 1984 A
4469110 Slama Sep 1984 A
4476003 Frank et al. Oct 1984 A
4477314 Richter et al. Oct 1984 A
4478976 Goertz et al. Oct 1984 A
4483924 Tsuji et al. Nov 1984 A
4484987 Gough Nov 1984 A
4494950 Fischell Jan 1985 A
4499249 Nakagawa et al. Feb 1985 A
4506680 Stokes Mar 1985 A
4509531 Ward Apr 1985 A
4512348 Uchigaki et al. Apr 1985 A
RE31916 Oswin et al. Jun 1985 E
4522690 Venkatsetty Jun 1985 A
4524114 Samuels et al. Jun 1985 A
4526661 Steckhan et al. Jul 1985 A
4526948 Resnick Jul 1985 A
4527240 Kvitash Jul 1985 A
4530696 Bisera et al. Jul 1985 A
4534356 Papadakis Aug 1985 A
4534825 Koning et al. Aug 1985 A
4538616 Rogoff Sep 1985 A
4543955 Schroeppel Oct 1985 A
4544869 Pittaway Oct 1985 A
4545382 Higgins et al. Oct 1985 A
4552840 Riffer Nov 1985 A
4554927 Fussell Nov 1985 A
4560534 Kung et al. Dec 1985 A
4561443 Hogrefe et al. Dec 1985 A
4569589 Neufeld Feb 1986 A
4571292 Liu et al. Feb 1986 A
4573994 Fischell et al. Mar 1986 A
4577642 Stokes Mar 1986 A
4581336 Malloy et al. Apr 1986 A
4595011 Phillips Jun 1986 A
4595479 Kimura et al. Jun 1986 A
4614760 Homan et al. Sep 1986 A
4619754 Niki et al. Oct 1986 A
4619793 Lee Oct 1986 A
4627445 Garcia et al. Dec 1986 A
4627908 Miller Dec 1986 A
4633878 Bombardien Jan 1987 A
4633881 Moore et al. Jan 1987 A
4637403 Garcia et al. Jan 1987 A
RE32361 Duggan Feb 1987 E
4648408 Hutcheson et al. Mar 1987 A
4650547 Gough Mar 1987 A
4653513 Dombrowski Mar 1987 A
4654197 Lilja et al. Mar 1987 A
4655880 Liu Apr 1987 A
4655885 Hill et al. Apr 1987 A
4658463 Sugita et al. Apr 1987 A
4663824 Kenmochi May 1987 A
4671288 Gough Jun 1987 A
4674652 Aten et al. Jun 1987 A
4679562 Luksha Jul 1987 A
4680268 Clark, Jr. Jul 1987 A
4681111 Silvian Jul 1987 A
4682602 Prohaska Jul 1987 A
4684537 Graetzel et al. Aug 1987 A
4685463 Williams Aug 1987 A
4686624 Blum et al. Aug 1987 A
4698582 Braun et al. Oct 1987 A
4703756 Gough et al. Nov 1987 A
4711245 Higgins et al. Dec 1987 A
4711251 Stokes Dec 1987 A
4714462 DiDomenico Dec 1987 A
4717673 Wrighton et al. Jan 1988 A
4718893 Dorman Jan 1988 A
4721601 Wrighton et al. Jan 1988 A
4721677 Clark, Jr. Jan 1988 A
4726378 Kaplan Feb 1988 A
4726716 McGuire Feb 1988 A
4731051 Fischell Mar 1988 A
4731726 Allen, III Mar 1988 A
4747828 Tseo May 1988 A
4749985 Corsberg Jun 1988 A
4750496 Reinhart Jun 1988 A
4753652 Langer et al. Jun 1988 A
4755173 Konopka Jul 1988 A
4757022 Shults et al. Jul 1988 A
4758323 Davis et al. Jul 1988 A
4759371 Franetzki Jul 1988 A
4759828 Young et al. Jul 1988 A
4764416 Ueyama et al. Aug 1988 A
4776944 Janata et al. Oct 1988 A
4777953 Ash et al. Oct 1988 A
4779618 Mund et al. Oct 1988 A
4781798 Gough Nov 1988 A
4784736 Lonsdale et al. Nov 1988 A
4787398 Garcia et al. Nov 1988 A
4795707 Niiyama et al. Jan 1989 A
4796634 Huntsman et al. Jan 1989 A
4803243 Fujimoto et al. Feb 1989 A
4803625 Fu et al. Feb 1989 A
4803726 Levine et al. Feb 1989 A
4805624 Yao et al. Feb 1989 A
4805625 Wyler Feb 1989 A
4810470 Burkhardt et al. Mar 1989 A
4813424 Wilkins Mar 1989 A
4815469 Cohen et al. Mar 1989 A
4820399 Senda et al. Apr 1989 A
4822337 Newhouse et al. Apr 1989 A
4826810 Aoki May 1989 A
4830959 McNeil et al. May 1989 A
4832034 Pizziconi May 1989 A
4832797 Vadgama et al. May 1989 A
4835372 Gombrich et al. May 1989 A
RE32947 Dormer et al. Jun 1989 E
4837049 Byers et al. Jun 1989 A
4838887 Idriss Jun 1989 A
4840893 Hill et al. Jun 1989 A
RE32974 Porat et al. Jul 1989 E
4844076 Lesho et al. Jul 1989 A
4845035 Fanta et al. Jul 1989 A
4848351 Finch Jul 1989 A
4849458 Reed et al. Jul 1989 A
4852573 Kennedy Aug 1989 A
4854322 Ash et al. Aug 1989 A
4856340 Garrison Aug 1989 A
4857713 Brown Aug 1989 A
4858617 Sanders Aug 1989 A
4870561 Love et al. Sep 1989 A
4871351 Feingold Oct 1989 A
4871440 Nagata et al. Oct 1989 A
4874499 Smith et al. Oct 1989 A
4874500 Madou et al. Oct 1989 A
4883057 Broderick Nov 1989 A
4889744 Quaid Dec 1989 A
4890620 Gough Jan 1990 A
4890621 Hakky Jan 1990 A
4894137 Takizawa et al. Jan 1990 A
4896142 Aycox et al. Jan 1990 A
4897162 Lewandowski et al. Jan 1990 A
4897173 Nankai et al. Jan 1990 A
4897457 Nakamura et al. Jan 1990 A
4899839 Dessertine et al. Feb 1990 A
4909908 Ross et al. Mar 1990 A
4911794 Parce et al. Mar 1990 A
4917800 Lonsdale et al. Apr 1990 A
4919141 Zier et al. Apr 1990 A
4919767 Vadgama et al. Apr 1990 A
4920969 Suzuki May 1990 A
4920977 Haynes May 1990 A
4923586 Katayama et al. May 1990 A
4925268 Iyer et al. May 1990 A
4927407 Dorman May 1990 A
4927516 Yamaguchi et al. May 1990 A
4931795 Gord Jun 1990 A
4934369 Maxwell Jun 1990 A
4935105 Churchouse Jun 1990 A
4935345 Guilbeau et al. Jun 1990 A
4936956 Wrighton Jun 1990 A
4938860 Wogoman Jul 1990 A
4942127 Wada et al. Jul 1990 A
4944299 Silvian Jul 1990 A
4945045 Forrest et al. Jul 1990 A
4950378 Nagata Aug 1990 A
4953552 DeMarzo Sep 1990 A
4954129 Giuliani et al. Sep 1990 A
4955861 Enegren et al. Sep 1990 A
4957115 Selker Sep 1990 A
4958632 Duggan Sep 1990 A
4963595 Ward et al. Oct 1990 A
4968400 Shimomura et al. Nov 1990 A
4969468 Byers et al. Nov 1990 A
4970145 Bennetto et al. Nov 1990 A
4974929 Curry Dec 1990 A
4979509 Hakky Dec 1990 A
4984929 Rock et al. Jan 1991 A
4986271 Wilkins Jan 1991 A
4986671 Sun et al. Jan 1991 A
4990845 Gord Feb 1991 A
4991582 Byers et al. Feb 1991 A
4992794 Brouwers Feb 1991 A
4994068 Hufnagie Feb 1991 A
4994167 Shults et al. Feb 1991 A
4995402 Smith et al. Feb 1991 A
5000180 Kuypers et al. Mar 1991 A
5001054 Wagner Mar 1991 A
5002054 Ash et al. Mar 1991 A
5002572 Picha Mar 1991 A
5007427 Suzuki et al. Apr 1991 A
5007929 Quaid Apr 1991 A
5016172 Dessertine May 1991 A
5016201 Bryan et al. May 1991 A
5016631 Hogrefe et al. May 1991 A
5019974 Beckers May 1991 A
5027499 Prohaska Jul 1991 A
5030333 Clark, Jr. Jul 1991 A
5034112 Murase et al. Jul 1991 A
5034192 Wrighton et al. Jul 1991 A
5035860 Kleingeld et al. Jul 1991 A
5036860 Leigh et al. Aug 1991 A
5036861 Sembrowich et al. Aug 1991 A
5037527 Hayashi et al. Aug 1991 A
5047044 Smith et al. Sep 1991 A
5049487 Phillips et al. Sep 1991 A
5050612 Matsumura Sep 1991 A
5055171 Peck Oct 1991 A
5058592 Whisler Oct 1991 A
5059654 Hou et al. Oct 1991 A
5063081 Cozzette et al. Nov 1991 A
5067491 Taylor et al. Nov 1991 A
5068536 Rosenthal Nov 1991 A
5070535 Hochmair et al. Dec 1991 A
5073500 Saito et al. Dec 1991 A
5074977 Cheung et al. Dec 1991 A
5077476 Rosenthal Dec 1991 A
5078854 Burgess et al. Jan 1992 A
5082550 Rishpon et al. Jan 1992 A
5082786 Nakamoto Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5088981 Howson et al. Feb 1992 A
5089112 Skotheim et al. Feb 1992 A
5094951 Rosenberg Mar 1992 A
5095904 Seligman et al. Mar 1992 A
5096560 Takai et al. Mar 1992 A
5096836 Macho et al. Mar 1992 A
5097834 Skrabal Mar 1992 A
5101814 Palti Apr 1992 A
5106365 Hernandez Apr 1992 A
5108564 Szuminsky et al. Apr 1992 A
5108889 Smith et al. Apr 1992 A
5109850 Blanco et al. May 1992 A
5111539 Hiruta et al. May 1992 A
5111818 Suzuji et al. May 1992 A
5114678 Crawford et al. May 1992 A
5120420 Nankai et al. Jun 1992 A
5120421 Glass et al. Jun 1992 A
5122925 Inpyn Jun 1992 A
5126034 Carter et al. Jun 1992 A
5126247 Palmer et al. Jun 1992 A
5130009 Marsoner et al. Jul 1992 A
5131441 Simpson et al. Jul 1992 A
5133856 Yamaguchi et al. Jul 1992 A
5134391 Okada Jul 1992 A
5135003 Souma Aug 1992 A
5137028 Nishimura Aug 1992 A
5139023 Stanley et al. Aug 1992 A
5140393 Hijikihigawa et al. Aug 1992 A
5140985 Schroeder et al. Aug 1992 A
5141868 Shanks et al. Aug 1992 A
5147725 Pinchuk Sep 1992 A
5153827 Coutre et al. Oct 1992 A
5161532 Joseph Nov 1992 A
5165407 Wilson et al. Nov 1992 A
5168046 Hamamoto et al. Dec 1992 A
5171689 Kawaguri et al. Dec 1992 A
5174291 Schoonen et al. Dec 1992 A
5176644 Srisathapat et al. Jan 1993 A
5176662 Bartholomew et al. Jan 1993 A
5182707 Cooper et al. Jan 1993 A
5184359 Tsukamura et al. Feb 1993 A
5185256 Nankai et al. Feb 1993 A
5190041 Palti Mar 1993 A
5192415 Yoshioka et al. Mar 1993 A
5192416 Wang et al. Mar 1993 A
5193539 Schulman et al. Mar 1993 A
5193540 Schulman et al. Mar 1993 A
5197322 Indravudh Mar 1993 A
5198192 Saito et al. Mar 1993 A
5198367 Aizawa et al. Mar 1993 A
5198771 Fidler et al. Mar 1993 A
5200051 Cozzette et al. Apr 1993 A
5202261 Musho et al. Apr 1993 A
5205920 Oyama et al. Apr 1993 A
5206145 Cattell Apr 1993 A
5208147 Kagenow et al. May 1993 A
5208154 Weaver et al. May 1993 A
5209229 Gilli May 1993 A
5215887 Saito Jun 1993 A
5216597 Beckers Jun 1993 A
5217442 Davis Jun 1993 A
5217595 Smith et al. Jun 1993 A
5227042 Zawodzinski et al. Jul 1993 A
5229282 Yoshioka et al. Jul 1993 A
5231988 Wernicke et al. Aug 1993 A
5232668 Grant et al. Aug 1993 A
5235003 Ward et al. Aug 1993 A
5243983 Tarr et al. Sep 1993 A
5246867 Lakowicz et al. Sep 1993 A
5249576 Goldberger et al. Oct 1993 A
5250439 Musho et al. Oct 1993 A
5251126 Kahn et al. Oct 1993 A
5257971 Lord et al. Nov 1993 A
5257980 Van Antwerp et al. Nov 1993 A
5259769 Cruise et al. Nov 1993 A
5261401 Baker et al. Nov 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264103 Yoshioka et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5264106 McAleer et al. Nov 1993 A
5265888 Yamamoto et al. Nov 1993 A
5266179 Nankai et al. Nov 1993 A
5269212 Peters et al. Dec 1993 A
5269891 Colin Dec 1993 A
5271736 Picha Dec 1993 A
5271815 Wong Dec 1993 A
5272060 Hamamoto et al. Dec 1993 A
5275159 Griebel Jan 1994 A
5276610 Maeda et al. Jan 1994 A
5278079 Gubinski et al. Jan 1994 A
5279294 Anderson et al. Jan 1994 A
5281319 Kaneko et al. Jan 1994 A
5282848 Schmitt Feb 1994 A
5282950 Dietze et al. Feb 1994 A
5284140 Allen et al. Feb 1994 A
5284156 Schramm et al. Feb 1994 A
5284570 Savage et al. Feb 1994 A
5284748 Mroczkowski et al. Feb 1994 A
5285513 Kaufman et al. Feb 1994 A
5285792 Sjoquist et al. Feb 1994 A
5286362 Hoenes et al. Feb 1994 A
5286364 Yacynych et al. Feb 1994 A
5288636 Pollmann et al. Feb 1994 A
5291887 Stanley et al. Mar 1994 A
5293546 Tadros et al. Mar 1994 A
5293877 O'Hara et al. Mar 1994 A
5299571 Mastrototaro Apr 1994 A
5304127 Kawahara et al. Apr 1994 A
5304468 Phillips et al. Apr 1994 A
5307263 Brown Apr 1994 A
5309919 Snell et al. May 1994 A
5310469 Cunningham et al. May 1994 A
5310885 Maier et al. May 1994 A
5312361 Zadini et al. May 1994 A
5314450 Thompson May 1994 A
5314471 Brauker et al. May 1994 A
5316008 Suga et al. May 1994 A
5318521 Slettenmark Jun 1994 A
5320098 Davidson Jun 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5324303 Strong et al. Jun 1994 A
5324316 Schulman et al. Jun 1994 A
5326356 Della Valle et al. Jul 1994 A
5326449 Cunningham Jul 1994 A
5328460 Lord et al. Jul 1994 A
5330521 Cohen Jul 1994 A
5330634 Wong et al. Jul 1994 A
5331555 Hashimoto et al. Jul 1994 A
5331966 Bennett et al. Jul 1994 A
5337258 Dennis Aug 1994 A
5337747 Neftel Aug 1994 A
5340722 Wolfbeis et al. Aug 1994 A
5342409 Mullett Aug 1994 A
5342789 Chick et al. Aug 1994 A
5343869 Pross et al. Sep 1994 A
5344454 Clarke et al. Sep 1994 A
5348788 White Sep 1994 A
5350407 McClure et al. Sep 1994 A
5352348 Young et al. Oct 1994 A
5352351 White Oct 1994 A
5354319 Wyborny et al. Oct 1994 A
5354449 Band et al. Oct 1994 A
5356348 Bellio et al. Oct 1994 A
5356786 Heller et al. Oct 1994 A
5358514 Schulman et al. Oct 1994 A
5360404 Novacek et al. Nov 1994 A
5364797 Olson et al. Nov 1994 A
5366609 White et al. Nov 1994 A
5368028 Palti Nov 1994 A
5368224 Richardson et al. Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5370622 Livingston et al. Dec 1994 A
5371687 Holmes, II et al. Dec 1994 A
5371734 Fischer Dec 1994 A
5372133 Hogen Dec 1994 A
5372427 Padovani et al. Dec 1994 A
5372719 Afejan et al. Dec 1994 A
5375604 Kelly et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5376251 Kaneko et al. Dec 1994 A
5377258 Bro Dec 1994 A
5378628 Gratzel et al. Jan 1995 A
5379238 Stark Jan 1995 A
5380422 Negishis et al. Jan 1995 A
5380536 Hubbell et al. Jan 1995 A
5382346 Uenoyama et al. Jan 1995 A
5384028 Ito Jan 1995 A
5387327 Khan Feb 1995 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5393903 Gratzel et al. Feb 1995 A
5395504 Saurer et al. Mar 1995 A
5397848 Yang et al. Mar 1995 A
5399823 McCusker Mar 1995 A
5400782 Beaubiah Mar 1995 A
5408999 Singh et al. Apr 1995 A
5410471 Alyfuku et al. Apr 1995 A
5410474 Fox Apr 1995 A
5411536 Armstrong May 1995 A
5411647 Johnson et al. May 1995 A
5411866 Luong May 1995 A
5413690 Kost et al. May 1995 A
5422246 Koopal et al. Jun 1995 A
5425361 Fenzlein et al. Jun 1995 A
5426032 Phillips Jun 1995 A
5429129 Lovejoy et al. Jul 1995 A
5431160 Wilkins Jul 1995 A
5431691 Snell et al. Jul 1995 A
5431921 Thombre Jul 1995 A
5433710 Van Antwerp et al. Jul 1995 A
5437973 Vadgama et al. Aug 1995 A
5437999 Diebold et al. Aug 1995 A
5438984 Schoendorfer Aug 1995 A
5445611 Eppstein et al. Aug 1995 A
5445920 Saito Aug 1995 A
5451260 Versteeg et al. Sep 1995 A
5452173 Brannon et al. Sep 1995 A
5453199 Afejan et al. Sep 1995 A
5453278 Chan et al. Sep 1995 A
5456692 Smith, Jr. et al. Oct 1995 A
5456940 Funderburk Oct 1995 A
5458140 Eppstein et al. Oct 1995 A
5460618 Harreld Oct 1995 A
5462051 Oka et al. Oct 1995 A
5462064 D'Angelo et al. Oct 1995 A
5462525 Srisathapat et al. Oct 1995 A
5462645 Albery et al. Oct 1995 A
5466218 Srisathapat et al. Nov 1995 A
5469846 Khan Nov 1995 A
5472317 Field et al. Dec 1995 A
5474552 Palti Dec 1995 A
5476460 Montalvo Dec 1995 A
5476776 Wilkins Dec 1995 A
5477855 Schindler et al. Dec 1995 A
5482008 Stafford et al. Jan 1996 A
5482473 Lord et al. Jan 1996 A
5484404 Schulman et al. Jan 1996 A
5487751 Radons et al. Jan 1996 A
5489414 Schreiber et al. Feb 1996 A
5491474 Suni et al. Feb 1996 A
5494562 Maley et al. Feb 1996 A
5496453 Uenoyama et al. Mar 1996 A
5497772 Schulman et al. Mar 1996 A
5501665 Jhuboo et al. Mar 1996 A
5501956 Wada et al. Mar 1996 A
5502396 Desarzens et al. Mar 1996 A
5505709 Funderburk Apr 1996 A
5505713 Van Antwerp et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5508171 Walling et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5513636 Palti May 1996 A
5514103 Srisathapat et al. May 1996 A
5514253 Davis et al. May 1996 A
5514718 Lewis et al. May 1996 A
5518006 Mawhirt et al. May 1996 A
5520787 Hanagan et al. May 1996 A
5522865 Schulman et al. Jun 1996 A
5525511 D'Costa Jun 1996 A
5526120 Jina et al. Jun 1996 A
5527307 Srisathapat et al. Jun 1996 A
5529676 Maley et al. Jun 1996 A
5531679 Schulman et al. Jul 1996 A
5531878 Vadgama et al. Jul 1996 A
5538007 Gorman Jul 1996 A
5538511 Van Antwerp et al. Jul 1996 A
5540828 Yacynych Jul 1996 A
5544651 Wilk Aug 1996 A
5545152 Funderburk et al. Aug 1996 A
5545191 Mann et al. Aug 1996 A
5545220 Andrews et al. Aug 1996 A
5545223 Neuenfeldt et al. Aug 1996 A
5549113 Halleck et al. Aug 1996 A
5549115 Morgan et al. Aug 1996 A
5549675 Neuenfeldt et al. Aug 1996 A
5551427 Altman Sep 1996 A
5551953 Lattin et al. Sep 1996 A
5552027 Birkle et al. Sep 1996 A
5553616 Ham et al. Sep 1996 A
5554166 Lange et al. Sep 1996 A
5556524 Albers Sep 1996 A
5558640 Pfeiler et al. Sep 1996 A
5560357 Faupei et al. Oct 1996 A
5562713 Silvian Oct 1996 A
5564439 Picha Oct 1996 A
5565085 Ikeda et al. Oct 1996 A
5567302 Song et al. Oct 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569186 Lord et al. Oct 1996 A
5569212 Brown Oct 1996 A
5569462 Martinson et al. Oct 1996 A
5571395 Park et al. Nov 1996 A
5571682 Jacobs et al. Nov 1996 A
5573506 Vasko Nov 1996 A
5573647 Maley et al. Nov 1996 A
5575895 Ikeda et al. Nov 1996 A
5575930 Tietje-Girault et al. Nov 1996 A
5580527 Bell et al. Dec 1996 A
5580794 Allen Dec 1996 A
5582184 Erickson et al. Dec 1996 A
5582593 Hultman Dec 1996 A
5582697 Ikeda et al. Dec 1996 A
5582698 Flaherty et al. Dec 1996 A
5584813 Livingston et al. Dec 1996 A
5584876 Bruchman et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5587273 Yan et al. Dec 1996 A
5589045 Hyodo Dec 1996 A
5589326 Deng et al. Dec 1996 A
5589563 Ward et al. Dec 1996 A
5590651 Shaffer et al. Jan 1997 A
5593440 Brauker et al. Jan 1997 A
5593852 Heller et al. Jan 1997 A
5594906 Holmes, II et al. Jan 1997 A
5596150 Arndy et al. Jan 1997 A
5596994 Bro Jan 1997 A
5601435 Quy Feb 1997 A
5601694 Maley et al. Feb 1997 A
5605152 Slate et al. Feb 1997 A
5607565 Azarnia et al. Mar 1997 A
5609575 Larson et al. Mar 1997 A
5611900 Worden et al. Mar 1997 A
5615671 Schoonen et al. Apr 1997 A
5616222 Maley et al. Apr 1997 A
5617851 Lipkovker Apr 1997 A
5623925 Swenson et al. Apr 1997 A
5624537 Turner et al. Apr 1997 A
5628309 Brown May 1997 A
5628310 Rao et al. May 1997 A
5628890 Carter et al. May 1997 A
5629981 Nerlikar May 1997 A
5637095 Nason et al. Jun 1997 A
5640764 Strojnik Jun 1997 A
5640954 Pfeiffer et al. Jun 1997 A
5642365 Murakami et al. Jun 1997 A
5643212 Coutre et al. Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5650062 Ikeda et al. Jul 1997 A
5651767 Schulman et al. Jul 1997 A
5651869 Yoshioka et al. Jul 1997 A
5653239 Pompei et al. Aug 1997 A
5653735 Chen et al. Aug 1997 A
5653756 Clarke et al. Aug 1997 A
5653863 Genshaw et al. Aug 1997 A
5658250 Blomquist et al. Aug 1997 A
5658330 Carlisle et al. Aug 1997 A
5660163 Schulman et al. Aug 1997 A
5662694 Lidman et al. Sep 1997 A
5665065 Colman et al. Sep 1997 A
5665222 Heller et al. Sep 1997 A
5667983 Abel et al. Sep 1997 A
5670031 Hintsche et al. Sep 1997 A
5676820 Wang et al. Oct 1997 A
5678571 Brown Oct 1997 A
5679690 Andre et al. Oct 1997 A
5680858 Hansen et al. Oct 1997 A
5682233 Brinda Oct 1997 A
5682884 Hill et al. Nov 1997 A
5686717 Knowles et al. Nov 1997 A
5686829 Girault Nov 1997 A
5695473 Olsen Dec 1997 A
5695623 Michel et al. Dec 1997 A
5695949 Galen et al. Dec 1997 A
5701894 Cherry et al. Dec 1997 A
5704354 Preidel et al. Jan 1998 A
5704922 Brown Jan 1998 A
5706807 Picha Jan 1998 A
5707502 McCaffrey et al. Jan 1998 A
5708247 McAleer et al. Jan 1998 A
5710630 Essenpreis et al. Jan 1998 A
5711001 Bussan et al. Jan 1998 A
5711297 Iliff Jan 1998 A
5711861 Ward et al. Jan 1998 A
5711862 Sakoda et al. Jan 1998 A
5711868 Maley et al. Jan 1998 A
5713353 Castano Feb 1998 A
5713888 Neuenfeldt et al. Feb 1998 A
5714123 Sohrab Feb 1998 A
5718234 Warden et al. Feb 1998 A
5720733 Brown Feb 1998 A
5720862 Hamamoto et al. Feb 1998 A
5721783 Anderson Feb 1998 A
5722397 Eppstein Mar 1998 A
5727548 Hill et al. Mar 1998 A
5728074 Castellano et al. Mar 1998 A
5730124 Yamauchi Mar 1998 A
5730654 Brown Mar 1998 A
5733336 Neuenfeldt et al. Mar 1998 A
5735273 Kurnik et al. Apr 1998 A
5735285 Albert et al. Apr 1998 A
5741211 Renirie et al. Apr 1998 A
5741330 Brauker et al. Apr 1998 A
5741634 Nozoe et al. Apr 1998 A
5741688 Oxenboll et al. Apr 1998 A
5743262 Lepper, Jr. et al. Apr 1998 A
5746217 Erickson et al. May 1998 A
5748103 Flach et al. May 1998 A
5749832 Vadgama et al. May 1998 A
5749907 Mann May 1998 A
5750926 Schulman et al. May 1998 A
5756632 Ward et al. May 1998 A
5770028 Maley et al. Jun 1998 A
5771001 Cobb Jun 1998 A
5771890 Tamada Jun 1998 A
5771891 Gozani Jun 1998 A
5772586 Heinonen et al. Jun 1998 A
5777060 Van Antwerp Jul 1998 A
5779665 Mastrototaro et al. Jul 1998 A
5781455 Hyodo Jul 1998 A
5782814 Brown et al. Jul 1998 A
5782912 Brauker et al. Jul 1998 A
5785681 Indravudh Jul 1998 A
5786439 Van Antwerp et al. Jul 1998 A
5786584 Button et al. Jul 1998 A
5787900 Butler et al. Aug 1998 A
5788678 Van Antwerp Aug 1998 A
5791344 Schulman et al. Aug 1998 A
5792117 Brown Aug 1998 A
5795774 Matsumoto et al. Aug 1998 A
5798065 Picha Aug 1998 A
5800387 Duffy et al. Sep 1998 A
5800420 Gross et al. Sep 1998 A
5800529 Brauker et al. Sep 1998 A
5804048 Wong et al. Sep 1998 A
5806517 Gerhardt et al. Sep 1998 A
5807315 Van Antwerp et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5807406 Brauker et al. Sep 1998 A
5811487 Schulz, Jr. et al. Sep 1998 A
5814599 Mitragotri et al. Sep 1998 A
5820551 Hill et al. Oct 1998 A
5820570 Erickson et al. Oct 1998 A
5820622 Gross et al. Oct 1998 A
5822715 Worthington et al. Oct 1998 A
5825488 Kohl et al. Oct 1998 A
5827179 Lichter et al. Oct 1998 A
5827183 Kurnik et al. Oct 1998 A
5827184 Netherly et al. Oct 1998 A
5828943 Brown Oct 1998 A
5830341 Gilmartin Nov 1998 A
5832448 Brown Nov 1998 A
5833603 Kovacs et al. Nov 1998 A
5834224 Ruger et al. Nov 1998 A
5836887 Oka et al. Nov 1998 A
5836989 Shelton Nov 1998 A
5837454 Cozzette et al. Nov 1998 A
5837546 Allen et al. Nov 1998 A
5837728 Purcell Nov 1998 A
5840020 Heinonen et al. Nov 1998 A
5840148 Campbell et al. Nov 1998 A
5840240 Stenoien et al. Nov 1998 A
5842983 Abel et al. Dec 1998 A
5843140 Strojnik Dec 1998 A
5846702 Deng et al. Dec 1998 A
5846744 Athey et al. Dec 1998 A
5851197 Marano et al. Dec 1998 A
5854078 Asher et al. Dec 1998 A
5854189 Kruse et al. Dec 1998 A
5857967 Frid et al. Jan 1999 A
5857983 Douglas et al. Jan 1999 A
5860917 Comanor et al. Jan 1999 A
5861009 Armstrong et al. Jan 1999 A
5861019 Sun et al. Jan 1999 A
5862803 Besson et al. Jan 1999 A
5871465 Vasko Feb 1999 A
5871514 Wiklund et al. Feb 1999 A
5872713 Douglas et al. Feb 1999 A
5872820 Upadrasta Feb 1999 A
5876484 Raskin et al. Mar 1999 A
5879163 Brown et al. Mar 1999 A
5879311 Duchon et al. Mar 1999 A
5879373 Roper et al. Mar 1999 A
5880829 Kauhaniemi et al. Mar 1999 A
5882494 Van Antwerp Mar 1999 A
5885211 Eppstein et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5887133 Brown et al. Mar 1999 A
5895235 Droz Apr 1999 A
5895371 Levitas et al. Apr 1999 A
5897493 Brown Apr 1999 A
5897578 Wiklund et al. Apr 1999 A
5898025 Burg et al. Apr 1999 A
5899855 Brown May 1999 A
5899931 Deschamp et al. May 1999 A
5904708 Goedeke May 1999 A
5913310 Brown Jun 1999 A
5913827 Gorman Jun 1999 A
5913998 Butler et al. Jun 1999 A
5914026 Blubaugh, Jr. et al. Jun 1999 A
5916445 Hjerten et al. Jun 1999 A
5917346 Gord Jun 1999 A
5918603 Brown Jul 1999 A
5919215 Wiklund et al. Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5928130 Schmidt Jul 1999 A
5931791 Saltzstein et al. Aug 1999 A
5931814 Alex et al. Aug 1999 A
5933136 Brown Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935785 Reber et al. Aug 1999 A
5940801 Brown Aug 1999 A
5942979 Luppino Aug 1999 A
5944661 Swette et al. Aug 1999 A
5945345 Blatt et al. Aug 1999 A
5947749 Rathburn Sep 1999 A
5947921 Johnson et al. Sep 1999 A
5948512 Kubota et al. Sep 1999 A
5950632 Reber et al. Sep 1999 A
5951300 Brown Sep 1999 A
5951492 Douglas et al. Sep 1999 A
5951521 Mastrototaro et al. Sep 1999 A
5951836 McAleer et al. Sep 1999 A
5954643 Van Antwerp Sep 1999 A
5954685 Tierney Sep 1999 A
5954700 Kovelman Sep 1999 A
5954954 Houck et al. Sep 1999 A
5956501 Brown Sep 1999 A
5957854 Besson et al. Sep 1999 A
5957890 Mann et al. Sep 1999 A
5957903 Mirzaee et al. Sep 1999 A
5957958 Schulman et al. Sep 1999 A
5959050 Mosbach et al. Sep 1999 A
5960403 Brown Sep 1999 A
5961451 Reber et al. Oct 1999 A
5963132 Yoakum Oct 1999 A
5964804 Brauker et al. Oct 1999 A
5964993 Blubaugh, Jr. et al. Oct 1999 A
5965380 Heller et al. Oct 1999 A
5968839 Blatt et al. Oct 1999 A
5971922 Arita et al. Oct 1999 A
5971941 Simons et al. Oct 1999 A
5974124 Schlueter, Jr. et al. Oct 1999 A
5976085 Kimball et al. Nov 1999 A
5977476 Guha et al. Nov 1999 A
5981294 Blatt et al. Nov 1999 A
5985129 Gough et al. Nov 1999 A
5987352 Klein et al. Nov 1999 A
5987353 Khatchatrian et al. Nov 1999 A
5989409 Kurnik et al. Nov 1999 A
5994476 Shin et al. Nov 1999 A
5995860 Sun et al. Nov 1999 A
5997475 Bortz Dec 1999 A
5997476 Brown Dec 1999 A
5999848 Gord et al. Dec 1999 A
5999849 Gord et al. Dec 1999 A
6001067 Shults et al. Dec 1999 A
6001471 Bries et al. Dec 1999 A
6002954 Van Antwerp et al. Dec 1999 A
6002961 Mitragotri et al. Dec 1999 A
6004441 Fujiwara et al. Dec 1999 A
6007845 Domb Dec 1999 A
6011984 Van Antwerp et al. Jan 2000 A
6013113 Mika Jan 2000 A
6014577 Henning et al. Jan 2000 A
6015390 Krag Jan 2000 A
6016448 Busacker et al. Jan 2000 A
6017435 Hassard et al. Jan 2000 A
6018678 Mitragotri et al. Jan 2000 A
6023629 Tamada Feb 2000 A
6024699 Surwit et al. Feb 2000 A
6026320 Carlson et al. Feb 2000 A
6027445 Von Bahr Feb 2000 A
6027459 Shain et al. Feb 2000 A
6027692 Galen et al. Feb 2000 A
6032059 Henning et al. Feb 2000 A
6032199 Lim et al. Feb 2000 A
6033866 Guo et al. Mar 2000 A
6034622 Levine Mar 2000 A
6035237 Schulman et al. Mar 2000 A
6036924 Simons et al. Mar 2000 A
6040194 Chick et al. Mar 2000 A
6041253 Kost et al. Mar 2000 A
6043437 Schulman et al. Mar 2000 A
6048691 Maracas Apr 2000 A
6049727 Crothall Apr 2000 A
6051372 Bayerl et al. Apr 2000 A
6056718 Funderburk et al. May 2000 A
6057377 Sasaki et al. May 2000 A
6059946 Yukawa et al. May 2000 A
6063459 Velte May 2000 A
6063637 Arnold et al. May 2000 A
6066083 Slater et al. May 2000 A
6066243 Anderson et al. May 2000 A
6066448 Wohlstadter et al. May 2000 A
6067474 Schulman et al. May 2000 A
6068615 Brown et al. May 2000 A
6071249 Cunningham et al. Jun 2000 A
6071251 Cunningham et al. Jun 2000 A
6071294 Simons et al. Jun 2000 A
6071391 Gotoh et al. Jun 2000 A
6071406 Tsou Jun 2000 A
6073049 Alt et al. Jun 2000 A
6081735 Diab et al. Jun 2000 A
6081736 Colvin et al. Jun 2000 A
6083523 Dionne et al. Jul 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6091976 Pfeiffer et al. Jul 2000 A
6093156 Cunningham et al. Jul 2000 A
6093167 Houben et al. Jul 2000 A
6093172 Funderburk et al. Jul 2000 A
6097831 Wieck et al. Aug 2000 A
6099484 Douglas et al. Aug 2000 A
6101478 Brown Aug 2000 A
6103033 Say et al. Aug 2000 A
6103533 Hassard et al. Aug 2000 A
6106780 Douglas et al. Aug 2000 A
6107083 Collins et al. Aug 2000 A
6110148 Brown et al. Aug 2000 A
6110152 Kovelman Aug 2000 A
6113537 Castano Sep 2000 A
6113578 Brown Sep 2000 A
6115634 Donders et al. Sep 2000 A
6117290 Say et al. Sep 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6121611 Lindsay et al. Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6122536 Sun et al. Sep 2000 A
6123827 Wong et al. Sep 2000 A
6125978 Ando et al. Oct 2000 A
6134461 Say et al. Oct 2000 A
6134504 Douglas et al. Oct 2000 A
6135978 Houben et al. Oct 2000 A
6139718 Kurnik et al. Oct 2000 A
6141573 Kurnik et al. Oct 2000 A
6142939 Eppstein et al. Nov 2000 A
6142972 Cheikh Nov 2000 A
6143164 Heller et al. Nov 2000 A
6144837 Quy Nov 2000 A
6144869 Berner et al. Nov 2000 A
6144871 Saito et al. Nov 2000 A
6144922 Douglas et al. Nov 2000 A
6148094 Kinsella Nov 2000 A
6150128 Uretsky Nov 2000 A
6151586 Brown Nov 2000 A
6153062 Saito et al. Nov 2000 A
6153069 Pottgen et al. Nov 2000 A
6154675 Juran et al. Nov 2000 A
6154676 Levine Nov 2000 A
6159147 Lichter et al. Dec 2000 A
6161095 Brown Dec 2000 A
6162611 Heller et al. Dec 2000 A
6162639 Douglas Dec 2000 A
6167362 Brown et al. Dec 2000 A
6167614 Tuttle et al. Jan 2001 B1
6168563 Brown Jan 2001 B1
6168568 Gavriely Jan 2001 B1
6170318 Lewis Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6180416 Kurnik et al. Jan 2001 B1
6186145 Brown Feb 2001 B1
6187062 Oweis et al. Feb 2001 B1
6189536 Martinez et al. Feb 2001 B1
6192891 Gravel et al. Feb 2001 B1
6193873 Ohara et al. Feb 2001 B1
6196970 Brown Mar 2001 B1
6198957 Green Mar 2001 B1
6200265 Walsh et al. Mar 2001 B1
6200772 Vadgama et al. Mar 2001 B1
6201979 Kurnik et al. Mar 2001 B1
6201980 Darrow et al. Mar 2001 B1
6201993 Kruse et al. Mar 2001 B1
6206841 Cunningham et al. Mar 2001 B1
6206856 Mahurkar Mar 2001 B1
6207400 Kwon Mar 2001 B1
6208894 Schulman et al. Mar 2001 B1
6210272 Brown Apr 2001 B1
6210976 Sabbadini Apr 2001 B1
6212416 Ward et al. Apr 2001 B1
6212424 Robinson Apr 2001 B1
6214185 Offenbacher et al. Apr 2001 B1
6219565 Cupp et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6223083 Rosar Apr 2001 B1
6223471 Barber May 2001 B1
6224745 Baltruschat May 2001 B1
6230059 Duffin May 2001 B1
6231879 Li et al. May 2001 B1
6232130 Wolf May 2001 B1
6232370 Kubota et al. May 2001 B1
6232783 Merrill May 2001 B1
6233080 Brenner et al. May 2001 B1
6233471 Berner et al. May 2001 B1
6233539 Brown May 2001 B1
6239925 Ardrey et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6241862 McAleer et al. Jun 2001 B1
6241863 Monbouquette Jun 2001 B1
6246330 Nielsen Jun 2001 B1
6246992 Brown Jun 2001 B1
6248065 Brown Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6248093 Moberg Jun 2001 B1
6251260 Heller et al. Jun 2001 B1
6251280 Dai et al. Jun 2001 B1
6252032 Van Antwerp et al. Jun 2001 B1
6253804 Safabash Jul 2001 B1
6254586 Mann et al. Jul 2001 B1
6256522 Schultz Jul 2001 B1
6256643 Cork et al. Jul 2001 B1
6259587 Sheldon et al. Jul 2001 B1
6259937 Schulman et al. Jul 2001 B1
6260022 Brown Jul 2001 B1
6264825 Blackburn et al. Jul 2001 B1
6266645 Simpson Jul 2001 B1
6267724 Taylor Jul 2001 B1
6268161 Han et al. Jul 2001 B1
6268913 Rising Jul 2001 B1
6270445 Dean, Jr. et al. Aug 2001 B1
6272364 Kurnik Aug 2001 B1
6272480 Tresp et al. Aug 2001 B1
6274285 Gries et al. Aug 2001 B1
6274686 Mosbach et al. Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6280416 Van Antwerp et al. Aug 2001 B1
6280587 Matsumoto Aug 2001 B1
6281006 Heller et al. Aug 2001 B1
6283761 Joao Sep 2001 B1
6283943 Dy et al. Sep 2001 B1
6284126 Kurnik et al. Sep 2001 B1
6284478 Heller et al. Sep 2001 B1
6285897 Kilcoyne et al. Sep 2001 B1
6289238 Besson et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6294281 Heller Sep 2001 B1
6295463 Stenzler Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6298254 Tamada Oct 2001 B2
6299578 Kurnik et al. Oct 2001 B1
6299757 Feldman et al. Oct 2001 B1
6300002 Webb et al. Oct 2001 B1
6301499 Carlson et al. Oct 2001 B1
6302855 Knobbe et al. Oct 2001 B1
6304766 Colvin, Jr. et al. Oct 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309351 Kurnik et al. Oct 2001 B1
6309384 Harrington et al. Oct 2001 B1
6309526 Fujiwara et al. Oct 2001 B1
6309884 Cooper et al. Oct 2001 B1
6310110 Markowitz et al. Oct 2001 B1
6315721 Schulman et al. Nov 2001 B2
6315738 Nishikawa et al. Nov 2001 B1
6319540 Van Antwerp et al. Nov 2001 B1
6319566 Polanyi et al. Nov 2001 B1
6320357 Peters et al. Nov 2001 B1
6324428 Weinberg et al. Nov 2001 B1
6325978 Labuda et al. Dec 2001 B1
6325979 Hahn et al. Dec 2001 B1
6326160 Dunn et al. Dec 2001 B1
6329161 Heller et al. Dec 2001 B1
6329929 Weijand et al. Dec 2001 B1
6330426 Brown et al. Dec 2001 B2
6330464 Colvin, Jr. et al. Dec 2001 B1
6331518 Hemm et al. Dec 2001 B2
6334778 Brown Jan 2002 B1
6336900 Alleckson et al. Jan 2002 B1
6338790 Feldman et al. Jan 2002 B1
6340421 Vachon et al. Jan 2002 B1
6340588 Nova et al. Jan 2002 B1
6341232 Conn et al. Jan 2002 B1
6343225 Clark, Jr. Jan 2002 B1
6348640 Navot et al. Feb 2002 B1
6352505 Bortz Mar 2002 B1
6356776 Berner et al. Mar 2002 B1
6358237 Paukovits et al. Mar 2002 B1
6359444 Grimes Mar 2002 B1
6360888 McIvor et al. Mar 2002 B1
6363282 Nichols et al. Mar 2002 B1
6365670 Fry Apr 2002 B1
6366793 Bell et al. Apr 2002 B1
6366794 Moussy et al. Apr 2002 B1
6368141 Van Antwerp et al. Apr 2002 B1
6368272 Porumbescu Apr 2002 B1
6368274 Van Antwerp et al. Apr 2002 B1
6370410 Kurnik et al. Apr 2002 B2
6377828 Chaiken et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6379317 Kintzig et al. Apr 2002 B1
6383767 Polak May 2002 B1
6387048 Schulman et al. May 2002 B1
6391643 Chen et al. May 2002 B1
6393318 Conn et al. May 2002 B1
6398562 Butler et al. Jun 2002 B1
6398727 Bui et al. Jun 2002 B1
6402689 Scarantino et al. Jun 2002 B1
6402691 Peddicord et al. Jun 2002 B1
6405066 Essenpreis et al. Jun 2002 B1
6406066 Uegane Jun 2002 B1
6406426 Reuss et al. Jun 2002 B1
6409674 Brockway et al. Jun 2002 B1
6413393 Van Antwerp et al. Jul 2002 B1
6416471 Kumar et al. Jul 2002 B1
6416651 Millar Jul 2002 B1
6418332 Mastrototaro et al. Jul 2002 B1
6418346 Nelson et al. Jul 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6424867 Snell et al. Jul 2002 B1
6427088 Bowman, IV et al. Jul 2002 B1
6434409 Pfeiffer et al. Aug 2002 B1
6438414 Conn et al. Aug 2002 B1
6440068 Brown et al. Aug 2002 B1
6441747 Khair et al. Aug 2002 B1
6442433 Linberg Aug 2002 B1
6442637 Hawkins et al. Aug 2002 B1
6443942 Van Antwerp et al. Sep 2002 B2
6447448 Ishikawa et al. Sep 2002 B1
6447542 Weadock Sep 2002 B1
6454710 Ballerstadt et al. Sep 2002 B1
6459917 Gowda et al. Oct 2002 B1
6461496 Feldman et al. Oct 2002 B1
6462162 Van Antwerp et al. Oct 2002 B2
6464687 Ishikawa et al. Oct 2002 B1
6464848 Matsumoto Oct 2002 B1
6464849 Say et al. Oct 2002 B1
6466810 Ward et al. Oct 2002 B1
6468222 Mault et al. Oct 2002 B1
6469526 Franklin Oct 2002 B1
6471645 Warkentin et al. Oct 2002 B1
6471689 Joseph et al. Oct 2002 B1
6472122 Schulman et al. Oct 2002 B1
6475180 Peterson et al. Nov 2002 B2
6475750 Han et al. Nov 2002 B1
6477392 Honigs et al. Nov 2002 B1
6477395 Schulman et al. Nov 2002 B2
6478736 Mault Nov 2002 B1
6480730 Darrow et al. Nov 2002 B2
6481440 Gielen et al. Nov 2002 B2
6482158 Mault Nov 2002 B2
6482604 Kwon Nov 2002 B2
6484045 Holker et al. Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6485138 Kubota et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6487429 Hockersmith et al. Nov 2002 B2
6494830 Wessel Dec 2002 B1
6496728 Li et al. Dec 2002 B2
6498043 Schulman et al. Dec 2002 B1
6498941 Jackson Dec 2002 B1
6505059 Kollias et al. Jan 2003 B1
6510329 Heckel Jan 2003 B2
6512939 Colvin et al. Jan 2003 B1
6513532 Mault et al. Feb 2003 B2
6514718 Heller et al. Feb 2003 B2
6515593 Stark et al. Feb 2003 B1
6520326 McIvor et al. Feb 2003 B2
6520997 Pekkarinen et al. Feb 2003 B1
6526298 Khalil et al. Feb 2003 B1
6527729 Turcott Mar 2003 B1
6528584 Kennedy et al. Mar 2003 B2
6529755 Kurnik et al. Mar 2003 B2
6529772 Carlson et al. Mar 2003 B2
6530915 Eppstein et al. Mar 2003 B1
6534322 Sabbadini Mar 2003 B1
6534323 Sabbadini Mar 2003 B1
6534711 Pollack Mar 2003 B1
6535753 Raskas Mar 2003 B1
6537243 Henning et al. Mar 2003 B1
6537318 Ita et al. Mar 2003 B1
6540675 Aceti et al. Apr 2003 B2
6541107 Zhong et al. Apr 2003 B1
6544212 Galley et al. Apr 2003 B2
6545085 Kilgour et al. Apr 2003 B2
6546268 Ishikawa et al. Apr 2003 B1
6546269 Kurnik Apr 2003 B1
6547839 Zhang et al. Apr 2003 B2
6549796 Sohrab Apr 2003 B2
6551276 Mann et al. Apr 2003 B1
6551494 Heller et al. Apr 2003 B1
6551496 Moles et al. Apr 2003 B1
6553241 Mannheimer et al. Apr 2003 B2
6553244 Lesho et al. Apr 2003 B2
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558321 Burd et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6561978 Conn et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6564105 Starkweather et al. May 2003 B2
6565509 Say et al. May 2003 B1
6569521 Sheridan et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6571200 Mault May 2003 B1
6572545 Knobbe et al. Jun 2003 B2
6574490 Abbink et al. Jun 2003 B2
6575905 Knobbe et al. Jun 2003 B2
6576101 Heller et al. Jun 2003 B1
6576117 Iketaki et al. Jun 2003 B1
6577893 Besson et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6579498 Eglise Jun 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6584335 Haar et al. Jun 2003 B1
6585644 Lebel et al. Jul 2003 B2
6585675 O'Mahony et al. Jul 2003 B1
6585763 Keilman et al. Jul 2003 B1
6587705 Kim et al. Jul 2003 B1
6588644 Simon Jul 2003 B2
6589205 Meadows Jul 2003 B1
6589229 Connelly et al. Jul 2003 B1
6591125 Buse et al. Jul 2003 B1
6591126 Roeper et al. Jul 2003 B2
6594514 Berner et al. Jul 2003 B2
6595919 Berner et al. Jul 2003 B2
6595929 Stivoric et al. Jul 2003 B2
6602678 Kwon et al. Aug 2003 B2
6602909 Jarowski Aug 2003 B1
6605072 Struys et al. Aug 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607509 Bobroff et al. Aug 2003 B2
6607658 Heller et al. Aug 2003 B1
6610012 Mault Aug 2003 B2
6612306 Mault Sep 2003 B1
6612984 Kerr Sep 2003 B1
6613379 Ward et al. Sep 2003 B2
6615078 Burson et al. Sep 2003 B1
6616819 Liamos et al. Sep 2003 B1
6618603 Varalli et al. Sep 2003 B2
6618934 Feldman et al. Sep 2003 B1
6620106 Mault Sep 2003 B2
6627058 Chan Sep 2003 B1
6629776 Bell et al. Oct 2003 B2
6629934 Mault et al. Oct 2003 B2
6633772 Ford et al. Oct 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6635167 Batman et al. Oct 2003 B1
6638772 Douglas et al. Oct 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6642015 Vachon et al. Nov 2003 B2
6644321 Behm Nov 2003 B1
6645142 Braig et al. Nov 2003 B2
6645181 Lavi et al. Nov 2003 B1
6648821 Lebel et al. Nov 2003 B2
6653091 Dunn et al. Nov 2003 B1
6654625 Say et al. Nov 2003 B1
6659948 Lebel et al. Dec 2003 B2
6668196 Villegas et al. Dec 2003 B1
6671554 Gibson et al. Dec 2003 B2
6673596 Sayler et al. Jan 2004 B1
6673625 Satcher, Jr. et al. Jan 2004 B2
6682938 Satcher, Jr. et al. Jan 2004 B1
6683040 Bragulla et al. Jan 2004 B2
6683535 Utke Jan 2004 B1
6687522 Tamada Feb 2004 B2
6687546 Lebel et al. Feb 2004 B2
6689056 Kilcoyne et al. Feb 2004 B1
6689091 Bui et al. Feb 2004 B2
6689265 Heller et al. Feb 2004 B2
6693069 Korber et al. Feb 2004 B2
6694158 Polak Feb 2004 B2
6694191 Starkweather et al. Feb 2004 B2
6695860 Ward et al. Feb 2004 B1
6699218 Flaherty et al. Mar 2004 B2
6699383 Lemire et al. Mar 2004 B2
6702857 Brauker et al. Mar 2004 B2
6704587 Kumar et al. Mar 2004 B1
6705833 Tam et al. Mar 2004 B2
6708049 Berson et al. Mar 2004 B1
6711423 Colvin, Jr. Mar 2004 B2
6721587 Gough Apr 2004 B2
6723046 Lichtenstein et al. Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6730200 Stewart et al. May 2004 B1
6731976 Penn et al. May 2004 B2
6733446 Lebel et al. May 2004 B2
6734162 Van Antwerp et al. May 2004 B2
6736777 Kim et al. May 2004 B2
6737401 Kim et al. May 2004 B2
6738654 Sohrab May 2004 B2
6740075 Lebel et al. May 2004 B2
6741163 Roberts May 2004 B1
6741876 Scecina et al. May 2004 B1
6741877 Shults et al. May 2004 B1
6743635 Neel et al. Jun 2004 B2
6746582 Heller et al. Jun 2004 B2
6749587 Flaherty Jun 2004 B2
6750311 Van Antwerp et al. Jun 2004 B1
6758810 Lebel et al. Jul 2004 B2
6766183 Walsh et al. Jul 2004 B2
6766201 Von Arx et al. Jul 2004 B2
6768425 Flaherty et al. Jul 2004 B2
6770030 Schaupp et al. Aug 2004 B1
6770729 Van Antwerp et al. Aug 2004 B2
6771995 Kurnik et al. Aug 2004 B2
6773563 Matsumoto Aug 2004 B2
6773565 Kunimoto et al. Aug 2004 B2
6780297 Matsumoto et al. Aug 2004 B2
6780871 Glick et al. Aug 2004 B2
6784274 Van Antwerp et al. Aug 2004 B2
6790178 Mault et al. Sep 2004 B1
6793802 Lee et al. Sep 2004 B2
6794195 Colvin, Jr. Sep 2004 B2
6799149 Hartlaub Sep 2004 B2
6800451 Daniloff et al. Oct 2004 B2
6801041 Karinka et al. Oct 2004 B2
6801420 Talbot et al. Oct 2004 B2
6802957 Jung et al. Oct 2004 B2
6804544 Van Antwerp et al. Oct 2004 B2
6809507 Morgan et al. Oct 2004 B2
6809653 Mann et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6811533 Lebel et al. Nov 2004 B2
6811534 Bowman, IV et al. Nov 2004 B2
6811659 Vachon Nov 2004 B2
6812031 Carlsson Nov 2004 B1
6813516 Ujhelyi et al. Nov 2004 B2
6813519 Lebel et al. Nov 2004 B2
6815186 Clark, Jr. Nov 2004 B2
6816742 Kim et al. Nov 2004 B2
6835553 Han et al. Dec 2004 B2
RE38681 Kurnik et al. Jan 2005 E
6837858 Cunningham et al. Jan 2005 B2
6840912 Kloepfer et al. Jan 2005 B2
6844023 Schulman et al. Jan 2005 B2
6849237 Housefield et al. Feb 2005 B2
6850790 Berner et al. Feb 2005 B2
6852500 Hoss et al. Feb 2005 B1
6852694 Van Antwerp et al. Feb 2005 B2
6853854 Proniewicz et al. Feb 2005 B1
6855115 Fonseca et al. Feb 2005 B2
6856928 Harmon Feb 2005 B2
6858403 Han et al. Feb 2005 B2
6862465 Shults et al. Mar 2005 B2
6862466 Ackerman Mar 2005 B2
6869413 Langley et al. Mar 2005 B2
6872200 Mann et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6875386 Ward et al. Apr 2005 B1
6879849 Begic Apr 2005 B2
6881551 Heller et al. Apr 2005 B2
6882940 Potts et al. Apr 2005 B2
6885883 Parris et al. Apr 2005 B2
6891317 Pei et al. May 2005 B2
6892085 McIvor et al. May 2005 B2
6893552 Wang et al. May 2005 B1
6895263 Shin et al. May 2005 B2
6895265 Silver May 2005 B2
6899683 Mault et al. May 2005 B2
6899684 Mault et al. May 2005 B2
6902905 Burson et al. Jun 2005 B2
6904301 Raskas Jun 2005 B2
6907127 Kravitz et al. Jun 2005 B1
6915147 Lebel et al. Jul 2005 B2
6918874 Hatch et al. Jul 2005 B1
6922578 Eppstein et al. Jul 2005 B2
6922584 Wang et al. Jul 2005 B2
RE38775 Kurnik et al. Aug 2005 E
6923764 Aceti et al. Aug 2005 B2
6923936 Swanson et al. Aug 2005 B2
6927246 Noronha et al. Aug 2005 B2
6931327 Goode, Jr. et al. Aug 2005 B2
6932084 Estes et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6936006 Sabra Aug 2005 B2
6936029 Mann et al. Aug 2005 B2
6940590 Colvin, Jr. et al. Sep 2005 B2
6941163 Ford et al. Sep 2005 B2
6942518 Liamos et al. Sep 2005 B2
6946996 Koyama Sep 2005 B2
6949816 Brown et al. Sep 2005 B2
6950708 Bowman, IV et al. Sep 2005 B2
6952603 Gerber et al. Oct 2005 B2
6952604 DeNuzzio et al. Oct 2005 B2
6954673 Von Arx et al. Oct 2005 B2
6955650 Mault et al. Oct 2005 B2
6957102 Silver et al. Oct 2005 B2
6957107 Rogers et al. Oct 2005 B2
6958705 Lebel et al. Oct 2005 B2
6965791 Hitchcock et al. Nov 2005 B1
6968294 Gutta et al. Nov 2005 B2
6968375 Brown Nov 2005 B1
6971274 Olin Dec 2005 B2
6973706 Say et al. Dec 2005 B2
6974437 Lebel et al. Dec 2005 B2
6978182 Mazar et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6990366 Say et al. Jan 2006 B2
6991096 Gottlieb et al. Jan 2006 B2
6997907 Safabash et al. Feb 2006 B2
6997920 Mann et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
6999810 Berner et al. Feb 2006 B2
7003336 Holker et al. Feb 2006 B2
7003340 Say et al. Feb 2006 B2
7003341 Say et al. Feb 2006 B2
7004901 Fish Feb 2006 B2
7005857 Stiene et al. Feb 2006 B2
7011630 Desai et al. Mar 2006 B2
7016721 Lee et al. Mar 2006 B2
7018366 Easter Mar 2006 B2
7018568 Tierney Mar 2006 B2
7022072 Fox et al. Apr 2006 B2
7024236 Ford et al. Apr 2006 B2
7024245 Lebel et al. Apr 2006 B2
7025743 Mann et al. Apr 2006 B2
7029444 Shin et al. Apr 2006 B2
7034677 Steinthal et al. Apr 2006 B2
7039810 Nichols May 2006 B1
7041068 Freeman et al. May 2006 B2
7041468 Drucker et al. May 2006 B2
7049277 Bagulla et al. May 2006 B2
7052472 Miller et al. May 2006 B1
7052483 Wojcik May 2006 B2
7056302 Douglas Jun 2006 B2
7060059 Keith et al. Jun 2006 B2
7070580 Nielsen Jul 2006 B2
7072718 VonArx et al. Jul 2006 B2
7072802 Hartlaub Jul 2006 B2
7074307 Simpson et al. Jul 2006 B2
7081195 Simpson et al. Jul 2006 B2
7082334 Boute et al. Jul 2006 B2
7098803 Mann et al. Aug 2006 B2
7108778 Simpson et al. Sep 2006 B2
7109878 Mann et al. Sep 2006 B2
7110803 Shults et al. Sep 2006 B2
7113821 Sun et al. Sep 2006 B1
7115884 Walt et al. Oct 2006 B1
7118667 Lee Oct 2006 B2
7133710 Acosta et al. Nov 2006 B2
7134999 Brauker et al. Nov 2006 B2
7136689 Shults et al. Nov 2006 B2
7137964 Flaherty Nov 2006 B2
7150975 Tamada et al. Dec 2006 B2
7163511 Conn et al. Jan 2007 B2
7166074 Reghabit et al. Jan 2007 B2
7169289 Shulein et al. Jan 2007 B2
7171274 Starkweather et al. Jan 2007 B2
7177690 Woods et al. Feb 2007 B2
7183068 Burson et al. Feb 2007 B2
7183102 Monfre et al. Feb 2007 B2
7187528 Talbot et al. Mar 2007 B2
7189341 Li et al. Mar 2007 B2
7190988 Say et al. Mar 2007 B2
7192450 Brauker et al. Mar 2007 B2
7198606 Boecker et al. Apr 2007 B2
7203549 Schommer et al. Apr 2007 B2
7207974 Safabash et al. Apr 2007 B2
7215991 Besson et al. May 2007 B2
7225535 Feldman et al. Jun 2007 B2
7226978 Tapsak et al. Jun 2007 B2
7228163 Ackerman Jun 2007 B2
7233817 Yen Jun 2007 B2
7248929 Meadows et al. Jul 2007 B2
7261691 Asomani Aug 2007 B1
7267665 Steil et al. Sep 2007 B2
7276029 Goode, Jr. et al. Oct 2007 B2
7278983 Ireland et al. Oct 2007 B2
7295867 Berner et al. Nov 2007 B2
7299082 Feldman et al. Nov 2007 B2
7310544 Brister et al. Dec 2007 B2
7318816 Bobroff et al. Jan 2008 B2
7329239 Safabash et al. Feb 2008 B2
7335294 Heller et al. Feb 2008 B2
7354420 Steil et al. Apr 2008 B2
7364592 Carr-Brendel et al. Apr 2008 B2
7366556 Brister et al. Apr 2008 B2
7379765 Petisce et al. May 2008 B2
7384396 Samuels et al. Jun 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7406105 DelMain et al. Jul 2008 B2
7424318 Brister et al. Sep 2008 B2
7426408 DeNuzzio et al. Sep 2008 B2
7460898 Brister et al. Dec 2008 B2
7467003 Brister et al. Dec 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7494465 Brister et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7519408 Rasdal et al. Apr 2009 B2
7583990 Goode, Jr. et al. Sep 2009 B2
7591801 Brauker et al. Sep 2009 B2
7599726 Goode, Jr. et al. Oct 2009 B2
7613491 Boock et al. Nov 2009 B2
7615007 Shults et al. Nov 2009 B2
7618369 Hayter et al. Nov 2009 B2
7632228 Brauker et al. Dec 2009 B2
7637868 Saint et al. Dec 2009 B2
7640048 Dobbles et al. Dec 2009 B2
7651596 Petisce et al. Jan 2010 B2
7654956 Brister et al. Feb 2010 B2
7657297 Simpson et al. Feb 2010 B2
7711402 Shults et al. May 2010 B2
7713574 Brister et al. May 2010 B2
7715893 Kamath et al. May 2010 B2
20010011224 Brown Aug 2001 A1
20010016310 Brown et al. Aug 2001 A1
20010016682 Berner et al. Aug 2001 A1
20010016683 Darrow et al. Aug 2001 A1
20010020124 Tamada Sep 2001 A1
20010029340 Mault et al. Oct 2001 A1
20010032278 Brown et al. Oct 2001 A1
20010037060 Thompson et al. Nov 2001 A1
20010037069 Carlson et al. Nov 2001 A1
20010039504 Linberg et al. Nov 2001 A1
20010041830 Varalli et al. Nov 2001 A1
20010044581 Mault Nov 2001 A1
20010044588 Mault Nov 2001 A1
20010047125 Quy Nov 2001 A1
20010049096 Brown Dec 2001 A1
20010049470 Mault et al. Dec 2001 A1
20010051768 Schulman et al. Dec 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020002328 Tamada Jan 2002 A1
20020004640 Conn et al. Jan 2002 A1
20020009810 O'Connor et al. Jan 2002 A1
20020010414 Coston et al. Jan 2002 A1
20020016530 Brown Feb 2002 A1
20020019022 Dunn et al. Feb 2002 A1
20020019330 Murray et al. Feb 2002 A1
20020019586 Teller et al. Feb 2002 A1
20020019748 Brown Feb 2002 A1
20020022883 Burg Feb 2002 A1
20020023852 McIvor et al. Feb 2002 A1
20020026111 Ackerman Feb 2002 A1
20020026937 Mault Mar 2002 A1
20020027164 Mault et al. Mar 2002 A1
20020028995 Mault Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20020042090 Heller et al. Apr 2002 A1
20020042561 Schulman et al. Apr 2002 A1
20020045808 Ford et al. Apr 2002 A1
20020047867 Mault et al. Apr 2002 A1
20020053637 Conn et al. May 2002 A1
20020062069 Mault May 2002 A1
20020063060 Gascoyne et al. May 2002 A1
20020065453 Lesho et al. May 2002 A1
20020068858 Braig et al. Jun 2002 A1
20020068860 Clark, Jr. Jun 2002 A1
20020072858 Cheng Jun 2002 A1
20020077765 Mault Jun 2002 A1
20020077766 Mault Jun 2002 A1
20020081559 Brown et al. Jun 2002 A1
20020083461 Hutcheson et al. Jun 2002 A1
20020084196 Liamos et al. Jul 2002 A1
20020087056 Aceti et al. Jul 2002 A1
20020091312 Berner et al. Jul 2002 A1
20020099282 Knobbe et al. Jul 2002 A1
20020099997 Piret Jul 2002 A1
20020103425 Mault Aug 2002 A1
20020103499 Perez et al. Aug 2002 A1
20020106709 Potts et al. Aug 2002 A1
20020107433 Mault Aug 2002 A1
20020107476 Mann et al. Aug 2002 A1
20020109600 Mault et al. Aug 2002 A1
20020111547 Knobbe et al. Aug 2002 A1
20020119711 Van Antwerp et al. Aug 2002 A1
20020124017 Mault Sep 2002 A1
20020128594 Das et al. Sep 2002 A1
20020130042 Moerman et al. Sep 2002 A1
20020133378 Mault et al. Sep 2002 A1
20020151796 Koulik Oct 2002 A1
20020151816 Rich et al. Oct 2002 A1
20020155615 Novikov et al. Oct 2002 A1
20020161286 Gerber et al. Oct 2002 A1
20020161288 Shin et al. Oct 2002 A1
20020177764 Sohrab Nov 2002 A1
20020182241 Boerenstein et al. Dec 2002 A1
20020188185 Sohrab Dec 2002 A1
20020193885 Legeay et al. Dec 2002 A1
20020198513 Lebel et al. Dec 2002 A1
20030004457 Andersson Jan 2003 A1
20030006669 Pei et al. Jan 2003 A1
20030023171 Sato et al. Jan 2003 A1
20030023182 Mault et al. Jan 2003 A1
20030023317 Brauker et al. Jan 2003 A1
20030023461 Quintanilla et al. Jan 2003 A1
20030028089 Galley et al. Feb 2003 A1
20030028120 Mault et al. Feb 2003 A1
20030032077 Itoh et al. Feb 2003 A1
20030032867 Crothall et al. Feb 2003 A1
20030032868 Graskov et al. Feb 2003 A1
20030032874 Rhodes et al. Feb 2003 A1
20030040683 Rule et al. Feb 2003 A1
20030042137 Mao et al. Mar 2003 A1
20030050537 Wessel Mar 2003 A1
20030050546 Desai et al. Mar 2003 A1
20030059631 Al-Lamee Mar 2003 A1
20030065254 Schulman et al. Apr 2003 A1
20030065257 Mault et al. Apr 2003 A1
20030065273 Mault et al. Apr 2003 A1
20030065274 Mault et al. Apr 2003 A1
20030065275 Mault et al. Apr 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030076082 Morgan et al. Apr 2003 A1
20030078481 McIvor et al. Apr 2003 A1
20030078560 Miller et al. Apr 2003 A1
20030097082 Purdy et al. May 2003 A1
20030100040 Bonnecaze et al. May 2003 A1
20030100821 Heller et al. May 2003 A1
20030105407 Pearce et al. Jun 2003 A1
20030108976 Braig et al. Jun 2003 A1
20030125612 Fox et al. Jul 2003 A1
20030125613 Enegren et al. Jul 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030134347 Heller et al. Jul 2003 A1
20030135100 Kim et al. Jul 2003 A1
20030135333 Aceti et al. Jul 2003 A1
20030153820 Berner et al. Aug 2003 A1
20030153821 Berner et al. Aug 2003 A1
20030158472 Sohrab Aug 2003 A1
20030158707 Doi Aug 2003 A1
20030168338 Gao et al. Sep 2003 A1
20030175806 Rule et al. Sep 2003 A1
20030176183 Drucker et al. Sep 2003 A1
20030176933 Lebel et al. Sep 2003 A1
20030181794 Rini et al. Sep 2003 A1
20030181851 Mann et al. Sep 2003 A1
20030181852 Mann et al. Sep 2003 A1
20030187338 Say et al. Oct 2003 A1
20030187525 Mann et al. Oct 2003 A1
20030188427 Say et al. Oct 2003 A1
20030191376 Samuels et al. Oct 2003 A1
20030191431 Mann et al. Oct 2003 A1
20030195403 Berner et al. Oct 2003 A1
20030195462 Mann et al. Oct 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030199790 Boecker et al. Oct 2003 A1
20030199791 Boecker et al. Oct 2003 A1
20030199903 Boecker et al. Oct 2003 A1
20030208110 Mault et al. Nov 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030208133 Mault Nov 2003 A1
20030208409 Mault Nov 2003 A1
20030211625 Cohan Nov 2003 A1
20030212317 Kovatchev et al. Nov 2003 A1
20030212346 Yuzhakov et al. Nov 2003 A1
20030212347 Sohrab Nov 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030217966 Tapsak et al. Nov 2003 A1
20030225437 Ferguson Dec 2003 A1
20030226695 Mault Dec 2003 A1
20030229514 Brown Dec 2003 A2
20030232370 Trifiro Dec 2003 A1
20030235817 Bartkowiak et al. Dec 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040011671 Shults et al. Jan 2004 A1
20040015063 DeNuzzio et al. Jan 2004 A1
20040015134 Lavi et al. Jan 2004 A1
20040018486 Dunn et al. Jan 2004 A1
20040024327 Brodnick Feb 2004 A1
20040030285 Lavi et al. Feb 2004 A1
20040030294 Mahurkar Feb 2004 A1
20040039256 Kawatahara et al. Feb 2004 A1
20040039298 Abreu Feb 2004 A1
20040039406 Jessen Feb 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040045879 Shults et al. Mar 2004 A1
20040054263 Moerman et al. Mar 2004 A1
20040059201 Ginsberg Mar 2004 A1
20040064068 DeNuzzio et al. Apr 2004 A1
20040068230 Estes et al. Apr 2004 A1
20040069164 Nakamura et al. Apr 2004 A1
20040072357 Stiene et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040074785 Holker Apr 2004 A1
20040078219 Kaylor Apr 2004 A1
20040096959 Stiene et al. May 2004 A1
20040106858 Say et al. Jun 2004 A1
20040106859 Say et al. Jun 2004 A1
20040108226 Polychronakos et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040122489 Mazar et al. Jun 2004 A1
20040133164 Funderburk et al. Jul 2004 A1
20040135684 Steinthal et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040143173 Reghabi et al. Jul 2004 A1
20040152187 Haight et al. Aug 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040153585 Kawatahara et al. Aug 2004 A1
20040162473 Sohrab Aug 2004 A1
20040164961 Bal et al. Aug 2004 A1
20040167383 Kim et al. Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040171921 Say et al. Sep 2004 A1
20040172284 Sullivan et al. Sep 2004 A1
20040173472 Jung et al. Sep 2004 A1
20040176672 Silver et al. Sep 2004 A1
20040176913 Kawatahara et al. Sep 2004 A1
20040186362 Brauker et al. Sep 2004 A1
20040186365 Jin et al. Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040199059 Brauker et al. Oct 2004 A1
20040202576 Aceti et al. Oct 2004 A1
20040204687 Mogensen et al. Oct 2004 A1
20040219664 Heller et al. Nov 2004 A1
20040225338 Lebel et al. Nov 2004 A1
20040236200 Say et al. Nov 2004 A1
20040236251 Roe et al. Nov 2004 A1
20040248204 Moerman Dec 2004 A1
20040249250 McGee et al. Dec 2004 A1
20040249253 Racchini et al. Dec 2004 A1
20040249254 Racchini et al. Dec 2004 A1
20040249999 Connolly et al. Dec 2004 A1
20040253736 Stout et al. Dec 2004 A1
20040254429 Yang Dec 2004 A1
20040254433 Bandis et al. Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20040260363 Von Arx et al. Dec 2004 A1
20040263354 Mann et al. Dec 2004 A1
20040267300 Mace Dec 2004 A1
20050003470 Nelson et al. Jan 2005 A1
20050004494 Perez et al. Jan 2005 A1
20050010087 Banet et al. Jan 2005 A1
20050010269 Lebel et al. Jan 2005 A1
20050027177 Shin et al. Feb 2005 A1
20050027179 Berner et al. Feb 2005 A1
20050027180 Goode, Jr. et al. Feb 2005 A1
20050027181 Goode, Jr. et al. Feb 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050027462 Goode, Jr. et al. Feb 2005 A1
20050027463 Goode, Jr. et al. Feb 2005 A1
20050031689 Shults et al. Feb 2005 A1
20050033132 Shults et al. Feb 2005 A1
20050038680 McMahon Feb 2005 A1
20050043598 Goode, Jr. et al. Feb 2005 A1
20050043894 Fernandez Feb 2005 A1
20050049473 Desai et al. Mar 2005 A1
20050051427 Brauker et al. Mar 2005 A1
20050051440 Simpson et al. Mar 2005 A1
20050054909 Petisce et al. Mar 2005 A1
20050056552 Simpson et al. Mar 2005 A1
20050090607 Tapsak et al. Apr 2005 A1
20050096519 DeNuzzio et al. May 2005 A1
20050112169 Brauker et al. May 2005 A1
20050113653 Fox et al. May 2005 A1
20050113657 Alarcon et al. May 2005 A1
20050113658 Jacobson et al. May 2005 A1
20050114068 Chey et al. May 2005 A1
20050118726 Schultz et al. Jun 2005 A1
20050121322 Say et al. Jun 2005 A1
20050124873 Shults et al. Jun 2005 A1
20050131346 Douglas Jun 2005 A1
20050137471 Haar et al. Jun 2005 A1
20050139489 Oliver et al. Jun 2005 A1
20050143635 Kamath et al. Jun 2005 A1
20050143636 Zhang et al. Jun 2005 A1
20050143675 Neel et al. Jun 2005 A1
20050148003 Kieth et al. Jul 2005 A1
20050154271 Rasdal et al. Jul 2005 A1
20050161346 Simpson et al. Jul 2005 A1
20050171503 Van Den Berghe et al. Aug 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050173245 Feldman et al. Aug 2005 A1
20050176136 Burd et al. Aug 2005 A1
20050177036 Shults et al. Aug 2005 A1
20050181012 Saint et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050182451 Griffin et al. Aug 2005 A1
20050187720 Goode, Jr. et al. Aug 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050195930 Spital et al. Sep 2005 A1
20050199494 Say et al. Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050203707 Tsutsui et al. Sep 2005 A1
20050211571 Schulein et al. Sep 2005 A1
20050214892 Kovatchev et al. Sep 2005 A1
20050215871 Feldman et al. Sep 2005 A1
20050215872 Berner et al. Sep 2005 A1
20050239154 Feldman et al. Oct 2005 A1
20050239156 Drucker et al. Oct 2005 A1
20050241957 Mao et al. Nov 2005 A1
20050242479 Petisce et al. Nov 2005 A1
20050245795 Goode, Jr. et al. Nov 2005 A1
20050245799 Brauker et al. Nov 2005 A1
20050251083 Carr-Brendel et al. Nov 2005 A1
20050261563 Zhou et al. Nov 2005 A1
20050261660 Choi Nov 2005 A1
20050267780 Ray et al. Dec 2005 A1
20050271546 Gerber et al. Dec 2005 A1
20050271547 Gerber et al. Dec 2005 A1
20050272640 Doyle, III et al. Dec 2005 A1
20050272985 Kotulla et al. Dec 2005 A1
20050277164 Drucker et al. Dec 2005 A1
20050287620 Heller et al. Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060001550 Mann et al. Jan 2006 A1
20060001551 Kraft et al. Jan 2006 A1
20060003398 Heller et al. Jan 2006 A1
20060004271 Peyser et al. Jan 2006 A1
20060007017 Mann et al. Jan 2006 A1
20060010098 Goodnow et al. Jan 2006 A1
20060015020 Neale et al. Jan 2006 A1
20060015024 Brister et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060019327 Brister et al. Jan 2006 A1
20060020186 Brister et al. Jan 2006 A1
20060020187 Brister et al. Jan 2006 A1
20060020188 Kamath et al. Jan 2006 A1
20060020189 Brister et al. Jan 2006 A1
20060020190 Kamath et al. Jan 2006 A1
20060020191 Brister et al. Jan 2006 A1
20060020192 Brister et al. Jan 2006 A1
20060025663 Talbot et al. Feb 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060036139 Brister et al. Feb 2006 A1
20060036140 Brister et al. Feb 2006 A1
20060036141 Kamath et al. Feb 2006 A1
20060036142 Brister et al. Feb 2006 A1
20060036143 Brister et al. Feb 2006 A1
20060036144 Brister et al. Feb 2006 A1
20060036145 Brister et al. Feb 2006 A1
20060036187 Vos et al. Feb 2006 A1
20060040402 Brauker et al. Feb 2006 A1
20060052679 Kotulla et al. Mar 2006 A1
20060058602 Kwiatkowski et al. Mar 2006 A1
20060063218 Bartkowiak et al. Mar 2006 A1
20060068208 Tapsak et al. Mar 2006 A1
20060074564 Bartkowiak et al. Apr 2006 A1
20060086624 Tapsak et al. Apr 2006 A1
20060100588 Brunnberg et al. May 2006 A1
20060155180 Brister et al. Jul 2006 A1
20060166629 Reggiardo Jul 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060183984 Dobbles et al. Aug 2006 A1
20060183985 Brister et al. Aug 2006 A1
20060189856 Petisce et al. Aug 2006 A1
20060189863 Heller et al. Aug 2006 A1
20060195029 Shults et al. Aug 2006 A1
20060198864 Shults et al. Sep 2006 A1
20060200019 Petisce et al. Sep 2006 A1
20060200020 Brister et al. Sep 2006 A1
20060200022 Brauker et al. Sep 2006 A1
20060211921 Brauker et al. Sep 2006 A1
20060222566 Brauker et al. Oct 2006 A1
20060224108 Brauker et al. Oct 2006 A1
20060224109 Steil et al. Oct 2006 A1
20060226985 Goodnow et al. Oct 2006 A1
20060247508 Fennell Nov 2006 A1
20060247985 Liamos et al. Nov 2006 A1
20060258761 Boock et al. Nov 2006 A1
20060258929 Goode, Jr. et al. Nov 2006 A1
20060270922 Brauker et al. Nov 2006 A1
20060270923 Brauker et al. Nov 2006 A1
20060281985 Ward et al. Dec 2006 A1
20070016381 Kamath et al. Jan 2007 A1
20070017805 Hodges et al. Jan 2007 A1
20070027381 Stafford Feb 2007 A1
20070027384 Brister et al. Feb 2007 A1
20070027385 Brister et al. Feb 2007 A1
20070032706 Kamath et al. Feb 2007 A1
20070032717 Brister et al. Feb 2007 A1
20070032718 Shults et al. Feb 2007 A1
20070038044 Dobbles et al. Feb 2007 A1
20070045902 Brauker et al. Mar 2007 A1
20070049873 Hansen et al. Mar 2007 A1
20070060814 Stafford Mar 2007 A1
20070066873 Kamath et al. Mar 2007 A1
20070073129 Shah et al. Mar 2007 A1
20070078320 Stafford Apr 2007 A1
20070078321 Mazza et al. Apr 2007 A1
20070078322 Stafford Apr 2007 A1
20070093704 Brister et al. Apr 2007 A1
20070106135 Sloan et al. May 2007 A1
20070149873 Say et al. Jun 2007 A1
20070149874 Say et al. Jun 2007 A1
20070149875 Ouyang et al. Jun 2007 A1
20070151869 Heller et al. Jul 2007 A1
20070161879 Say et al. Jul 2007 A1
20070161880 Say et al. Jul 2007 A1
20070163880 Woo et al. Jul 2007 A1
20070173706 Neinast et al. Jul 2007 A1
20070179370 Say et al. Aug 2007 A1
20070179372 Say et al. Aug 2007 A1
20070191699 Say et al. Aug 2007 A1
20070191700 Say et al. Aug 2007 A1
20070191701 Feldman et al. Aug 2007 A1
20070197889 Brister et al. Aug 2007 A1
20070197890 Boock et al. Aug 2007 A1
20070203407 Hoss et al. Aug 2007 A1
20070203408 Say et al. Aug 2007 A1
20070203410 Say et al. Aug 2007 A1
20070203411 Say et al. Aug 2007 A1
20070203966 Brauker et al. Aug 2007 A1
20070208244 Brauker et al. Sep 2007 A1
20070208245 Brauker et al. Sep 2007 A1
20070208246 Brauker et al. Sep 2007 A1
20070208247 Say et al. Sep 2007 A1
20070213610 Say et al. Sep 2007 A1
20070213611 Simpson et al. Sep 2007 A1
20070215491 Heller et al. Sep 2007 A1
20070218097 Heller et al. Sep 2007 A1
20070232878 Kovatchev et al. Oct 2007 A1
20070235331 Simpson et al. Oct 2007 A1
20070244380 Say et al. Oct 2007 A1
20070249919 Say et al. Oct 2007 A1
20070249920 Say et al. Oct 2007 A1
20070249922 Peyser et al. Oct 2007 A1
20080009692 Stafford Jan 2008 A1
20080017522 Heller et al. Jan 2008 A1
20080021436 Wolpert et al. Jan 2008 A1
20080021666 Goode, Jr. et al. Jan 2008 A1
20080029391 Mao et al. Feb 2008 A1
20080033254 Kamath et al. Feb 2008 A1
20080033271 Say et al. Feb 2008 A1
20080039702 Hayter et al. Feb 2008 A1
20080045824 Tapsak et al. Feb 2008 A1
20080071156 Brister et al. Mar 2008 A1
20080076997 Peyser et al. Mar 2008 A1
20080083617 Simpson et al. Apr 2008 A1
20080086039 Heller et al. Apr 2008 A1
20080086040 Heller et al. Apr 2008 A1
20080086041 Heller et al. Apr 2008 A1
20080086042 Brister et al. Apr 2008 A1
20080086043 Heller et al. Apr 2008 A1
20080086044 Brister et al. Apr 2008 A1
20080086273 Shults et al. Apr 2008 A1
20080091094 Heller et al. Apr 2008 A1
20080091095 Heller et al. Apr 2008 A1
20080091096 Say et al. Apr 2008 A1
20080108942 Brister et al. May 2008 A1
20080154101 Jain et al. Jun 2008 A1
20080167543 Say et al. Jul 2008 A1
20080183061 Goode et al. Jul 2008 A1
20080183399 Goode et al. Jul 2008 A1
20080188731 Brister et al. Aug 2008 A1
20080189051 Goode et al. Aug 2008 A1
20080194935 Brister et al. Aug 2008 A1
20080194936 Goode et al. Aug 2008 A1
20080194937 Goode et al. Aug 2008 A1
20080194938 Brister et al. Aug 2008 A1
20080195232 Carr-Brendel et al. Aug 2008 A1
20080195967 Goode et al. Aug 2008 A1
20080197024 Simpson et al. Aug 2008 A1
20080200788 Brister et al. Aug 2008 A1
20080200789 Brister et al. Aug 2008 A1
20080200791 Simpson et al. Aug 2008 A1
20080208025 Shults et al. Aug 2008 A1
20080214914 Say et al. Sep 2008 A1
20080214915 Brister et al. Sep 2008 A1
20080214918 Brister et al. Sep 2008 A1
20080228051 Shults et al. Sep 2008 A1
20080228054 Shults et al. Sep 2008 A1
20080242961 Brister et al. Oct 2008 A1
20080262329 Say et al. Oct 2008 A1
20080262469 Brister et al. Oct 2008 A1
20080269672 Say et al. Oct 2008 A1
20080275313 Brister et al. Nov 2008 A1
20080287764 Rasdal et al. Nov 2008 A1
20080287765 Rasdal et al. Nov 2008 A1
20080287766 Rasdal et al. Nov 2008 A1
20080296155 Shults et al. Dec 2008 A1
20080306368 Goode et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306435 Kamath et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20080319292 Say et al. Dec 2008 A1
20090011449 Karinka et al. Jan 2009 A1
20090012379 Goode et al. Jan 2009 A1
20090018424 Kamath et al. Jan 2009 A1
20090018425 Ouyang et al. Jan 2009 A1
20090030294 Petisce et al. Jan 2009 A1
20090030297 Miller et al. Jan 2009 A1
20090036758 Brauker et al. Feb 2009 A1
20090036763 Brauker et al. Feb 2009 A1
20090043181 Brauker et al. Feb 2009 A1
20090043182 Brauker et al. Feb 2009 A1
20090043525 Brauker et al. Feb 2009 A1
20090043541 Brauker et al. Feb 2009 A1
20090043542 Brauker et al. Feb 2009 A1
20090045055 Rhodes et al. Feb 2009 A1
20090062633 Brauker et al. Mar 2009 A1
20090062634 Say et al. Mar 2009 A1
20090062635 Brauker et al. Mar 2009 A1
20090069655 Say et al. Mar 2009 A1
20090069656 Say et al. Mar 2009 A1
20090069657 Say et al. Mar 2009 A1
20090069658 Say et al. Mar 2009 A1
20090076356 Simpson et al. Mar 2009 A1
20090076360 Brister et al. Mar 2009 A1
20090076361 Kamath et al. Mar 2009 A1
20090089999 Say et al. Apr 2009 A1
20090093696 Say et al. Apr 2009 A1
20090099432 Say et al. Apr 2009 A1
20090099435 Say et al. Apr 2009 A1
20090099436 Brister et al. Apr 2009 A1
20090124877 Goode, Jr. et al. May 2009 A1
20090124878 Goode et al. May 2009 A1
20090124879 Brister et al. May 2009 A1
20090124964 Leach et al. May 2009 A1
20090131768 Simpson et al. May 2009 A1
20090131769 Leach et al. May 2009 A1
20090131776 Simpson et al. May 2009 A1
20090131777 Simpson et al. May 2009 A1
20090137886 Shariati et al. May 2009 A1
20090137887 Shariati et al. May 2009 A1
20090143659 Li et al. Jun 2009 A1
20090143660 Brister et al. Jun 2009 A1
20090156919 Brister et al. Jun 2009 A1
20090156924 Shariati et al. Jun 2009 A1
20090163781 Say et al. Jun 2009 A1
20090163788 Say et al. Jun 2009 A1
20090163789 Say et al. Jun 2009 A1
20090163790 Brister et al. Jun 2009 A1
20090163791 Brister et al. Jun 2009 A1
20090171179 Say et al. Jul 2009 A1
20090173628 Say et al. Jul 2009 A1
20090177054 Say et al. Jul 2009 A1
20090177055 Say et al. Jul 2009 A1
20090177056 Say et al. Jul 2009 A1
20090177057 Say et al. Jul 2009 A1
20090177058 Say et al. Jul 2009 A1
20090177059 Say et al. Jul 2009 A1
20090177060 Say et al. Jul 2009 A1
20090177061 Say et al. Jul 2009 A1
20090177062 Say et al. Jul 2009 A1
20090177063 Say et al. Jul 2009 A1
20090177064 Say et al. Jul 2009 A1
20090177065 Say et al. Jul 2009 A1
20090177066 Say et al. Jul 2009 A1
20090178459 Li et al. Jul 2009 A1
20090182212 Say et al. Jul 2009 A1
20090182213 Say et al. Jul 2009 A1
20090182214 Say et al. Jul 2009 A1
20090182215 Say et al. Jul 2009 A1
20090182217 Li et al. Jul 2009 A1
20090187088 Say et al. Jul 2009 A1
20090187089 Say et al. Jul 2009 A1
20090187090 Say et al. Jul 2009 A1
20090187091 Say et al. Jul 2009 A1
20090187092 Say et al. Jul 2009 A1
20090187093 Say et al. Jul 2009 A1
20090187094 Say et al. Jul 2009 A1
20090187095 Say et al. Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192368 Say et al. Jul 2009 A1
20090192369 Say et al. Jul 2009 A1
20090192370 Say et al. Jul 2009 A1
20090192371 Say et al. Jul 2009 A1
20090192372 Say et al. Jul 2009 A1
20090192373 Say et al. Jul 2009 A1
20090192374 Say et al. Jul 2009 A1
20090192375 Say et al. Jul 2009 A1
20090192376 Say et al. Jul 2009 A1
20090192377 Say et al. Jul 2009 A1
20090192378 Say et al. Jul 2009 A1
20090192379 Say et al. Jul 2009 A1
20090192380 Shariati et al. Jul 2009 A1
20090192722 Shariati et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090192751 Kamath et al. Jul 2009 A1
20090198115 Say et al. Aug 2009 A1
20090198116 Say et al. Aug 2009 A1
20090198175 Say et al. Aug 2009 A1
20090203978 Say et al. Aug 2009 A1
20090203981 Brauker et al. Aug 2009 A1
20090204341 Brauker et al. Aug 2009 A1
20090209838 Say et al. Aug 2009 A1
20090216100 Ebner et al. Aug 2009 A1
20090216101 Say et al. Aug 2009 A1
20090216103 Brister et al. Aug 2009 A1
20090227940 Say et al. Sep 2009 A1
20090227941 Say et al. Sep 2009 A1
20090228214 Say et al. Sep 2009 A1
20090240120 Mensinger et al. Sep 2009 A1
20090240128 Mensinger et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090242399 Kamath et al. Oct 2009 A1
20090242425 Kamath et al. Oct 2009 A1
20090247855 Boock et al. Oct 2009 A1
20090247856 Boock et al. Oct 2009 A1
20090281406 McGarraugh et al. Nov 2009 A1
20090287073 Boock et al. Nov 2009 A1
20090287074 Shults et al. Nov 2009 A1
20090299155 Yang et al. Dec 2009 A1
20090299156 Simpson et al. Dec 2009 A1
20090299162 Brauker et al. Dec 2009 A1
20090299276 Brauker et al. Dec 2009 A1
20100010324 Brauker et al. Jan 2010 A1
20100010331 Brauker et al. Jan 2010 A1
20100010332 Brauker et al. Jan 2010 A1
20100016687 Brauker et al. Jan 2010 A1
20100016698 Rasdal et al. Jan 2010 A1
20100022855 Brauker et al. Jan 2010 A1
20100030038 Brauker et al. Feb 2010 A1
20100030053 Goode, Jr. et al. Feb 2010 A1
20100030484 Brauker et al. Feb 2010 A1
20100030485 Brauker et al. Feb 2010 A1
20100036215 Goode, Jr. et al. Feb 2010 A1
20100036216 Goode, Jr. et al. Feb 2010 A1
20100036222 Goode, Jr. et al. Feb 2010 A1
20100036223 Goode, Jr. et al. Feb 2010 A1
20100036225 Goode, Jr. et al. Feb 2010 A1
20100041971 Goode, Jr. et al. Feb 2010 A1
20100045465 Brauker et al. Feb 2010 A1
20100049024 Saint et al. Feb 2010 A1
20100063373 Kamath et al. Mar 2010 A1
20100076283 Simpson et al. Mar 2010 A1
20100081908 Dobbles et al. Apr 2010 A1
20100081910 Brister et al. Apr 2010 A1
20100087724 Brauker et al. Apr 2010 A1
20100096259 Zhang et al. Apr 2010 A1
20100099970 Shults et al. Apr 2010 A1
20100099971 Shults et al. Apr 2010 A1
20100119693 Tapsak et al. May 2010 A1
20100121169 Petisce et al. May 2010 A1
Foreign Referenced Citations (183)
Number Date Country
4401400 Jul 1995 DE
0010375 Apr 1980 EP
0026995 Apr 1981 EP
0048090 Mar 1982 EP
0078636 May 1983 EP
0080304 Jun 1983 EP
0098592 Jan 1984 EP
0107634 May 1984 EP
0125139 Nov 1984 EP
0127958 Dec 1984 EP
0136362 Apr 1985 EP
0170375 Feb 1986 EP
0177743 Apr 1986 EP
0184909 Jun 1986 EP
0206218 Dec 1986 EP
0230472 Aug 1987 EP
0241309 Oct 1987 EP
0245073 Nov 1987 EP
0255291 Feb 1988 EP
0278647 Aug 1988 EP
0320109 Jun 1989 EP
0353328 Feb 1990 EP
0359831 Mar 1990 EP
0368209 May 1990 EP
0368290 May 1990 EP
0390390 Oct 1990 EP
0396788 Nov 1990 EP
0400918 Dec 1990 EP
0453283 Oct 1991 EP
0512122 Nov 1992 EP
0535898 Apr 1993 EP
0539625 May 1993 EP
0561966 Oct 1994 EP
0286118 Jan 1995 EP
0776628 Jun 1997 EP
0800082 Oct 1997 EP
0817809 Jan 1998 EP
0838230 Apr 1998 EP
0880936 Dec 1998 EP
0885932 Dec 1998 EP
0967788 Dec 1999 EP
0970655 Jan 2000 EP
1034734 Sep 2000 EP
1048264 Nov 2000 EP
1077634 Feb 2001 EP
1078258 Feb 2001 EP
1355568 Oct 2003 EP
2187555 May 2010 EP
WO-8505119 Nov 1985 WO
WO-8600513 Jan 1986 WO
WO-8605339 Sep 1986 WO
WO-8700513 Jan 1987 WO
WO-8706040 Oct 1987 WO
WO-8902246 Mar 1989 WO
WO-8902720 Apr 1989 WO
WO-8905119 Jun 1989 WO
WO-8908713 Sep 1989 WO
WO-9000367 Jan 1990 WO
WO-9000738 Jan 1990 WO
WO-9005300 May 1990 WO
WO-9005910 May 1990 WO
WO-9010861 Sep 1990 WO
WO-9013021 Nov 1990 WO
WO-9101680 Feb 1991 WO
WO-9104704 Apr 1991 WO
WO-9115993 Oct 1991 WO
WO-9204153 Mar 1992 WO
WO-9207525 May 1992 WO
WO-9210584 Jun 1992 WO
WO-9213271 Aug 1992 WO
WO-9305703 Apr 1993 WO
WO-9314693 Aug 1993 WO
WO-9319701 Oct 1993 WO
WO-9420602 Sep 1994 WO
WO-9422367 Oct 1994 WO
WO-9427140 Nov 1994 WO
WO-9506240 Mar 1995 WO
WO-9507109 Mar 1995 WO
WO-9601611 Jan 1996 WO
WO-9607908 Mar 1996 WO
WO-9614026 May 1996 WO
WO-9625089 Aug 1996 WO
WO-9630431 Oct 1996 WO
WO-9632076 Oct 1996 WO
WO-9635370 Nov 1996 WO
WO-9636296 Nov 1996 WO
WO-9701986 Jan 1997 WO
WO-9702847 Jan 1997 WO
WO-9706727 Feb 1997 WO
WO-9719344 May 1997 WO
WO-9720207 Jun 1997 WO
WO-9728737 Aug 1997 WO
WO-9741421 Nov 1997 WO
WO-9742882 Nov 1997 WO
WO-9742883 Nov 1997 WO
WO-9742886 Nov 1997 WO
WO-9742888 Nov 1997 WO
WO-9743962 Nov 1997 WO
WO-9746868 Dec 1997 WO
WO-9809167 Mar 1998 WO
WO-9810699 Mar 1998 WO
WO-9824358 Jun 1998 WO
WO-9824366 Jun 1998 WO
WO-9835053 Aug 1998 WO
WO-9852045 Nov 1998 WO
WO-9852293 Nov 1998 WO
WO-9856293 Dec 1998 WO
WO-9905966 Feb 1999 WO
WO-9913574 Mar 1999 WO
WO-9932883 Jul 1999 WO
WO-9948419 Sep 1999 WO
WO-9956613 Nov 1999 WO
WO-9958051 Nov 1999 WO
WO-9958973 Nov 1999 WO
WO-0013580 Mar 2000 WO
WO-0018294 Apr 2000 WO
WO-0019887 Apr 2000 WO
WO-0020626 Apr 2000 WO
WO-0032098 Jun 2000 WO
WO-0033065 Jun 2000 WO
WO-0049940 Aug 2000 WO
WO-0059370 Oct 2000 WO
WO-0059373 Oct 2000 WO
WO-0062664 Oct 2000 WO
WO-0062665 Oct 2000 WO
WO-0074753 Dec 2000 WO
WO-0078210 Dec 2000 WO
WO-0078992 Dec 2000 WO
WO-0112158 Feb 2001 WO
WO-0120019 Mar 2001 WO
WO-0120334 Mar 2001 WO
WO-0124038 Apr 2001 WO
WO-0133216 May 2001 WO
WO-0143660 Jun 2001 WO
WO-0152727 Jul 2001 WO
WO-0152935 Jul 2001 WO
WO-0154753 Aug 2001 WO
WO-0157238 Aug 2001 WO
WO-0157239 Aug 2001 WO
WO-0158348 Aug 2001 WO
WO-0167009 Sep 2001 WO
WO-0168901 Sep 2001 WO
WO-0169222 Sep 2001 WO
WO-0188524 Nov 2001 WO
WO-0188534 Nov 2001 WO
WO-0216905 Feb 2002 WO
WO-0217210 Feb 2002 WO
WO-0224065 Mar 2002 WO
WO-02058537 Aug 2002 WO
WO-02078512 Oct 2002 WO
WO-02082989 Oct 2002 WO
WO-02100266 Dec 2002 WO
WO-03072269 Sep 2003 WO
WO-03076893 Sep 2003 WO
WO-03082091 Oct 2003 WO
WO-03085372 Oct 2003 WO
WO-03101862 Dec 2003 WO
WO-2004061420 Jul 2004 WO
WO-2005041766 May 2005 WO
WO-2005089103 Sep 2005 WO
WO-2005026689 Oct 2005 WO
WO-2005119524 Dec 2005 WO
WO-2006024671 Mar 2006 WO
WO-2006079114 Jul 2006 WO
WO-2006086423 Aug 2006 WO
WO-2006105146 Oct 2006 WO
WO-2006118947 Nov 2006 WO
WO-2006119084 Nov 2006 WO
WO-2007002189 Jan 2007 WO
WO-2007016399 Feb 2007 WO
WO-2007027381 Mar 2007 WO
WO-2007027788 Mar 2007 WO
WO-2007041069 Apr 2007 WO
WO-2007041070 Apr 2007 WO
WO-2007041248 Apr 2007 WO
WO-2007051139 May 2007 WO
WO-2007056638 May 2007 WO
WO-2007101223 Sep 2007 WO
WO-2007120363 Oct 2007 WO
WO-2007126444 Nov 2007 WO
WO-2007053832 Dec 2007 WO
WO-2007143225 Dec 2007 WO
WO-2009029662 Mar 2009 WO
Related Publications (1)
Number Date Country
20080058625 A1 Mar 2008 US
Provisional Applications (2)
Number Date Country
60804170 Jun 2006 US
60804169 Jun 2006 US